Watch · 58/100 · medium confidence

ENSIGN GROUP, INC (ENSG) — Council Assessment

🟡 WATCH · Score 58/100 · medium confidence

A genuinely well-run, fortress-balance-sheet SNF compounder trading at a fair-not-cheap price, but under an unresolved short-seller cloud that strikes directly at the integrity of its profit model.

As of 2026-06-26. 18 lenses weighed in, 0 abstained. Sources: 6 filings, 18 news, 15 discussion, 1 earnings_call.

360 narrative — news & sentiment digest

ENSG — ENSIGN GROUP, INC.

Management commentary (earnings call)

Q3 2025 Results & Guidance (Nov 8, 2025 call)

Barry Porter (CEO) and team delivered strong results and raised full-year guidance:

EPS guidance raised to $6.48–$6.54 (midpoint +18.4% vs. FY2024), up from prior $6.34 guidance
Revenue guidance $5.05–$5.07B
Q3 results: GAAP diluted EPS $1.42 (+6% YoY); adjusted diluted EPS $1.64 (+18% YoY); consolidated revenue $1.3B (+19.8% YoY)

Key operational metrics:

Same-store occupancy: 83% (all-time high); transitioning ops: 84.4%
Skilled days (same-store): +5.1% YoY; transitioning: +10.9%
Medicare revenue growth: same-store +10%, transitioning +8.8%; Medicare days up 4.2% (same-store)
Managed care revenue: same-store +7.1%, transitioning +24.3%
CMS performance: 24% outperformance at state level; 10% advantage in 4–5-star ratings

Clinical & labor tone: Porter emphasized clinical quality as "key differentiator" and core to consistent financial performance. Management highlighted labor improvements: turnover down, wage growth stable, staffing agency usage declining despite higher occupancy.

Acquisitions & Capital Allocation:

Closed/transitioned 22 new ops in Q3 + since (45 total in 2025)
Added 1,857 skilled nursing beds, 109 senior living units across six states
Major deals: 11-facility California portfolio, 7-facility Utah "Stonehenge" portfolio
Standard Bear REIT added 11 properties; now 149 total (115 enzyme-affiliated, 35 third-party); Q3 FFO $19.3M; EBITDAAR-to-rent 2.5x
Capital deployed YTD: $240M+; net debt/EBITDA 1.86x; $593M available credit + $443.7M cash ($1B+ dry powder)
Dividend & buyback: Quarterly dividend $0.0625/share; 22-year streak of increases; $40–$100M repurchase authorization announced

Organic growth narrative (key theme): Porter stated 83% same-store occupancy leaves room for organic expansion equivalent to 8 new 100-bed facilities (to 85%) or 17 (to 88%), without adding fixed overhead. Management views this as "more powerful than acquisitions" for margin expansion. Noted mature ops consistently achieve mid-to-high 90s occupancy; emphasized long-term demographic tailwind (80+ U.S. population +50% by 2035; dependency ratio down 40%).

Deal market commentary: Chad Gingrey (Chief Development Officer) noted disciplined approach: "capital seems to flood into the industry…we remain disciplined" and avoid overpriced deals. Some markets (e.g., Texas) show "too rich" pricing from financial buyers; company comfortable with smaller, multi-market deals vs. mega-deals. Several deals lined up for Q1 2026.

Analyst Q&A excerpts:

Ben Hendrix (RBC): On skilled mix room to run & sustainability

Management: 5.1% YoY same-store growth "not abnormal" historically. Steady, consistent growth expected. Focus on adding services for acute providers & managed care partners. Spencer: Beacon example shows no cap even after five years; mature ops have "substantial upside." Only 31.7% of same-store days are skilled currently—"very large" opportunity.

AJ Rice (UBS): Deal environment, new markets (behavioral health)

Chad: Utah/California deals driven by seller readiness, long relationships, not special market conditions. Texas seeing financial buyer activity push prices unsustainably; company staying disciplined. AJ noted behavioral health units in pilot—strong traction, managed care asking for capacity. Response: "lots of traction…add more capacity…areas of success we hope to continue."

Raj Kumar (Stevens): Market share vs. demographic demand

Management: Increase in skilled mix driven by both demographics AND rising chronic illness/comorbidities in target population. Building clinical capabilities to serve higher acuity. Not necessarily major care-setting shift; more demand for higher acute within SNF setting.

Clark Murphy (Truest Securities): Contributor stories, Southeast expansion

Recently acquired facilities contributing 15.5% of Q3 revenue; will be higher in Q4. Newly acquired ops performing ahead of pro forma but far from full potential; company seeing "pretty exciting" early contributions. Southeast transitions (Alabama, Tennessee) "really, really good"; leaders and operators showing "significant signs." Portfolio continues to strengthen.

Management tone: Confident, disciplined, emphasis on long-term demographic tailwinds and organic potential. Acknowledged deal-market choppiness but framed it as immaterial given organic runway. Candid about cost-of-acquisitions and willingness to slow pace in irrational pricing environments.

Recent developments

Q3 2025 earnings (Nov 8, 2025): Guidance raised to $6.48–$6.54 EPS; revenue $5.05–$5.07B
22 acquisitions closed/transitioned in Q3 + since, including 11-facility California portfolio and 7-facility Utah ("Stonehenge") portfolio
Standard Bear REIT: 149 total properties (up 11 in Q3); expanding third-party tenant relationships
Stock repurchase: Authorized increased to $40M (June 2026 news); later expanded to $100M (June 2026)
Short-seller report (June 8, 2026): Hunterbrook issued report alleging understaffing, "patient neglect," metric-gaming. Stock fell ~8% on day; RBC Capital and analysts reiterated ratings. Lawyers (Kessler Topaz, Rosen Law Firm) filed class-action probes.
Q1 2026 earnings (late April 2026): Surpassed estimates (per press coverage)
Quarterly dividend: $0.0625/share maintained; 22-year increase streak

Bull narrative

Management & research consensus (pre-short report):

Organic growth engine: 83% same-store occupancy with runway to 85–88% without M&A; management quantifies as equivalent to 8–17 new 100-bed facilities. Margin accretive (no new fixed overhead).
Demographic tailwind: 80+ U.S. population +50% over next decade; dependency ratio declining 40%. "Undeniable" secular growth.
Clinical differentiation: 24% outperformance vs. peers in CMS surveys; 10% higher 4–5-star ratings. Claimed to underpin market share gains and occupancy strength.
Acquisition pipeline: 73 ops closed since 2024; ability to scale "onesie-tusies" and portfolios without centralized bottleneck (decentralized leadership, "AIT pipeline"). Examples (River Park, Beacon Harbor) show transformational turnarounds: occupancy 76% → 97% (15 months), EBIT +376%, revenue +54%.
Labor improvements: Turnover down, wage growth stable, agency usage declining. Positioned as sustainable advantage.
Capital strength: $1B+ dry powder, net debt/EBITDA 1.86x, 22-year dividend growth streak. Buying back stock at elevated valuations (confidence signal to some).
Managed care growth: +7–24% revenue growth; expanding partnerships and ACO involvement.

Retail bull sentiment (sparse in material):

@Maxwell_Osgood (June 24): bullish stance (no details given)
@ReigningTrades: compares favorably to PACS; "acquisition-driven model" positioning for breakout; in since $8, targeting $50 (long time horizon).
Options traders: $160 calls, 82% ROI over ~30 days (early June).

Bear narrative

Short-seller report (Hunterbrook, June 8, 2026):

Alleges understaffing as core profit driver ("100% of profitability")
Claims patient neglect (title: "Neglect" cited in stock drop headline)
Accuses management of metric gaming
Timing: hit during broader SNF industry downturn

Retail bear sentiment (June 2026):

@Easteregg: "Rekt" (terse, defeat signal)
@Smokesdrugs: speculates institutional dump; later: "classic" red day amid green market
@bettingonbiotech: "need to wait until dust settles"; notes Hunterbrook reports "typically rebound for one reason or another" but timing hit SNF sector when already weak; "allegations are well known"
@Wonderfulnewz: acknowledges bear thesis that understaffing drives profitability; notes management "never shy" about efficiency focus; concedes "bad PR"; observes Muddy Waters / Hunterbrook reports have tanked SNF names in the past; sees institutional base as potential rebound support

Implicit concerns:

Operational model critique: if clinical quality differential is real, why paired with understaffing allegations?
Regulatory/reputational risk: if labor underfunding substantiated, could draw state/federal scrutiny, reimbursement pressure, staff turnover risk
Cyclical SNF headwinds (broader industry stress) may amplify short report impact

Retail sentiment

Overall: Mixed with recent sharp bearish tilt (June 2026)

Pre-short report (through May 2026):

Moderate bullish: earnings beats, guidance raises, management confidence
Minimal retail chatter in material

Post-Hunterbrook (June 8 onward):

Initial shock (June 8–11): sharp selling, speculation on institutional unwind, references to Muddy Waters success in SNF shorts
Stabilization/conviction recovery (June 10–15): RBC reiterates; analysts reiterate ratings; some retail recognizing Hunterbrook timing (mid-industry weakness) and historical precedent for recoveries
Neutral drift (June 15–25): buyback expansion ($40M → $100M), dividend affirmation, Q2 earnings expectations ($1.85 EPS) suggest continued buy-side interest; "dust settling" narrative
Conviction level: Low — retail commentary sparse, mostly tactical (trades, options) or one-liners; limited deep discussion of allegations or rebuttal

Caveats

Short-seller allegations not independently verified. Hunterbrook report excerpts not provided; no management rebuttal in call material (call predates report by 7 months). Allegations of understaffing, neglect, and metric-gaming are serious but unvalidated in this briefing.
Earnings call transcript has transcription errors ("Enzine" vs. "Ensign," "pressure lease," "Enzine Group Bank" vs. Ensign Group). Accuracy of attributions somewhat compromised; material substantive content appears intact, but quotations should be spot-checked against official version.
Limited retail/forum discussion material. Twitter/X chatter is sparse, mostly emoji/sentiment signals. No substantive retail thesis development. Cannot reliably gauge retail conviction beyond "mixed with recent fear."
Class-action probes filed (Kessler Topaz, Rosen Law) as of late June 2026 — formal legal risk now in play, but scope and merit unknown from summaries provided.
No recent insider trading, board changes, or management commentary on allegations in material. Silent defense could read as either confidence or avoidance.
Seasonal and reimbursement risks acknowledged by management but not quantified. Medicare market basket +3.2% (Oct 2025) is positive, but state budget/policy shifts not forecasted.
Standard Bear (REIT subsidiary) complexity: Valuation, accounting, tenant diversification (now including third parties) adds opacity to consolidated earnings. FFO 2.5x rent coverage solid but relatively tight margin for error in adverse scenario.
Demographic thesis strong but long-dated. 50% growth by 2035 is 9 years out; execution risk, competitive

Bull case

ENSG is a disciplined, decentralized roll-up with real operational skill: it buys underperforming SNFs and drives occupancy from ~76% toward mid-90s, backed by demographic tailwinds (80+ population +50% by 2035). ROIC 14.2% vs WACC 7.7% is a genuine 650bps value-creating spread, achieved on a near-unlevered, net-cash balance sheet ($366M net cash, D/E 0.06). FCF of $493M exceeds net income ($344M) — clean earnings quality with no accrual flattery. Organic occupancy runway (83%→88%) offers 8–17 facility-equivalents of margin-accretive growth without new fixed overhead. The DCF pegs intrinsic value at $259 (base) with even the bear case ($200) above the $163 price, and the disruption lens rates the business nearly AI-proof. Multiple quality voices (Munger, Mauboussin, Greenblatt, valuation referee) rate it a Pass.

Bear case

The Hunterbrook short report (June 2026) alleges understaffing, patient neglect, and CMS metric-gaming — the claim that 'understaffing IS the profit model,' if even partially true, reframes the 14.2% ROIC as regulatory arbitrage rather than a durable moat. Two class-action probes (Kessler Topaz, Rosen) are live, and management has issued no substantive rebuttal — silence that every quality lens flagged. Valuation is not a bargain: P/E 27.7x, P/FCF 19.3x, P/B 4.27x, PEG 1.5, and the DCF is 81% terminal value, so the intrinsic value rests on sustained 12% growth that would collapse under staffing mandates or reimbursement cuts. The capex figure is stale (2019), likely overstating true normalized FCF for a 45-deal-a-year acquirer. Margins are structurally thin (8.5% operating), government-reimbursement-dependent, and the Standard Bear REIT adds accounting opacity. Graham and Schloss reject it outright on price/asset grounds.

Dissent — where the council disagrees

The panel splits sharply. The Pass camp (Munger 74, Mauboussin 74, Greenblatt 74, Damodaran referee 74, Dalio 72, disruption referee 72) sees a genuine franchise at a fair price with margin of safety. But the deep-value and forensic voices dissent hard: Schloss AVOIDS at 28 (4.27x book, at highs, no asset floor), Graham rejects on P/E×P/B of 118, and Bruce Greenwald's EPV work is the most damning — he pegs intrinsic value at ~$78/share (2.1x below the market price), arguing the entire premium is unproven growth. The forensic short-seller (48) and Druckenmiller (52, 'tape is breaking down') both refuse to buy into an unresolved integrity allegation. This matters because the quality bulls' 74 scores are explicitly conditional — every one of them writes 'IF the integrity concerns resolve cleanly.' The tension is that the bull case and the bear case are the same fact (lean staffing = high margins), interpreted as either operational excellence or regulatory exploitation. Until the Hunterbrook allegations are adjudicated, the Pass scores are effectively unearned.

Key risks

Hunterbrook allegations of understaffing/metric-gaming substantiated by regulatory action, triggering CMS star downgrades, reimbursement clawbacks, or staffing mandates that compress the thin 8.5% margin
Class-action litigation (Kessler Topaz, Rosen) escalating into material settlement costs and reputational damage with referral partners
DCF is 81% terminal value — any fade in growth or reimbursement cut collapses fair value toward current price or below
Stale capex data (2019) likely overstates true normalized FCF for a serial acquirer deploying $240M+/year
Government reimbursement (Medicare/Medicaid) dependency with no private-pay substitute in a fiscal-austerity scenario
Standard Bear REIT and operating-lease structure ($3.09B of liabilities not in stated debt) obscure true leverage and earnings quality

Catalysts

Management issuing a detailed, credible rebuttal to Hunterbrook with facility-level staffing data
Resolution or dismissal of the class-action probes
Continued organic occupancy gains toward 85–88% demonstrating margin expansion without acquisitions
Clean CMS survey results / regulatory audits validating the quality-differentiation narrative
Sustained FCF > net income over next 4–6 quarters without goodwill impairment
Further price pullback toward $120–135 (PEG ~1.0) that would convert several Watch votes to Buy

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $258.77/share vs price $163.05 → +59% (bear $199.93 · base $258.77 · bull $297.7).

Step	Value
Base free cash flow	$493M
FCF growth (yrs 1-5)	12.0% (revenue CAGR)
WACC (β 0.682)	7.7%
Terminal growth	2.5%
PV of explicit FCF	$2.8B
PV of terminal (residual) value	$11.9B (81% of EV)
Enterprise value	$14.7B
less Net debt	$-366M
= Equity value	$15.0B
/ Shares (58M) = intrinsic/share	$258.77

Short-sell evaluation

🔸 MARGINAL SHORT

There is a coherent short thesis — a serial acquirer at 27.7x earnings and 4.27x book, 81% terminal-value-dependent DCF, thin government-reimbursed margins, and a live short report alleging that the very profit engine (lean staffing) is a regulatory liability with two class actions attached. If Hunterbrook is substantiated by CMS action or a restatement, the moat narrative and multiple both compress hard. But this is a treacherous short: the balance sheet is a fortress (net cash $366M, D/E 0.06), FCF is robustly positive and exceeds net income (no cash-burn or accrual red flag), the demographic demand tailwind is durable, the business is essentially AI/disruption-proof, and the stock has already fallen ~25% from $218, pricing in meaningful fear. Shorting a well-capitalized, cash-generative compounder on an unproven allegation invites a violent squeeze if management rebuts credibly. This is a short only for specialists positioned around a specific regulatory catalyst — not a clean structural short.

Pros (the short could work)

Rich valuation on demonstrated fundamentals: P/E 27.7x, P/FCF 19.3x, P/B 4.27x, PEG 1.5 — no margin of safety on the downside
DCF is 81% terminal value; Greenwald's EPV pegs the business at ~$78 vs $163 — 2x overvaluation if growth disappoints
Live short report (Hunterbrook) + two class-action probes create an unquantified regulatory/legal catalyst; understaffing allegation strikes the core profit model
Stale (2019) capex figure likely overstates true FCF for a company doing 45 deals/year, meaning reported cash generation may be flattered
Thin, government-reimbursement-dependent margins (8.5% operating) with no pricing power — vulnerable to staffing mandates or reimbursement cuts
Serial-acquirer roll-up model accumulates goodwill/intangibles and integration risk; Standard Bear REIT adds accounting opacity

Cons (what kills the short)

Fortress balance sheet: net cash $366M, D/E 0.06, $1B+ dry powder — no financial distress path, so no forced-selling catalyst
Robust positive FCF that exceeds net income — the opposite of the classic short setup; no cash burn to exploit
Squeeze risk: stock already down 25% from $218, fear largely in the price; a credible management rebuttal could spark a sharp reversal
Durable, multi-decade demographic demand tailwind (80+ population +50% by 2035) and near-zero AI/disruption risk
22-year dividend growth streak, active buyback ($100M authorization), and disciplined M&A signal genuine quality and shareholder alignment
Allegations are unproven; RBC reiterated post-report — shorting on an unadjudicated thesis carries unlimited-downside asymmetry against a good business

Council scorecard

Lens	School	Stance	Score	Conf
Valuation Referee (Damodaran-style)	referee	🟢 pass	74	medium
Joel Greenblatt	value	🟢 pass	74	medium
Charlie Munger	quality	🟢 pass	74	medium
Michael Mauboussin	quality	🟢 pass	74	medium
Ray Dalio	risk	🟢 pass	72	medium
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	72	medium
Chuck Akre	quality	🟡 watch	62	medium
Warren Buffett	quality	🟡 watch	62	medium
Bruce Greenwald	value	🟡 watch	62	medium
Philip Fisher	growth	🟡 watch	58	medium
Peter Lynch	growth	🟡 watch	58	medium
Howard Marks	risk	🟡 watch	55	medium
Terry Smith (Fundsmith)	quality	🟡 watch	55	medium
Stanley Druckenmiller	risk	🟡 watch	52	medium
Benjamin Graham	value	🟡 watch	52	medium
Seth Klarman	value	🟡 watch	52	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟡 watch	48	medium
Walter Schloss	value	🔴 avoid	28	high

Member reasoning

Valuation Referee (Damodaran-style) — 🟢 pass · 74/100 · medium confidence

The DCF framework is well-applicable to ENSG: it has stable, forecastable cash flows ($492.7M FCF in FY2025), consistent revenue growth (18.5% 3-year CAGR), and a mature-enough business model (SNF/care facilities) to construct a defensible story-to-numbers valuation. The model's intrinsic value of $258.77/share vs. current price of $163.05 implies ~59% upside, which is a substantial margin of safety. However, the short-seller allegations (Hunterbrook, June 2026), class-action probes, and the Muddy Waters association inject meaningful uncertainty that warrants scoring below a clean 'pass.' Let me walk through the key inputs: (1) FCF growth at 12% (sourced from 18.5% revenue CAGR — defensibly conservative since margins are thin at 9.8% FCF margin and may compress); (2) WACC at 7.67% built on beta 0.682 — this is plausible for a healthcare services company with low leverage (D/E 0.06) but arguably slightly low given regulatory/litigation risk now in play; (3) terminal growth at 2.5% — at the high end of acceptable but not egregious given demographic tailwinds; (4) terminal value is 81.1% of enterprise value — this is high and sensitive to WACC and terminal growth assumptions, the classic vulnerability. Reverse-engineering the current price of $163: at $163 the market is embedding roughly 6-7% FCF growth with a ~8% WACC, or essentially a 'worry about execution and litigation' scenario — this is actually not heroic, suggesting the price does NOT demand perfection. ROIC at 14.2% meaningfully exceeds WACC of 7.67%, so growth is genuinely value-creating, not destructive. The sales-to-capital ratio appears healthy given low long-term debt ($137.5M) and strong FCF conversion (operating cash $564M vs. capex only $71.5M — though capex figure is flagged as from 2019, which is a data quality concern). Key concerns: the capex figure ($71.5M from 2019) is stale — actual maintenance+growth capex for a company doing 45 acquisitions annually is almost certainly higher, and FCF may be overstated if acquisition spend is partially embedded in operating cash flows or excluded. The short-seller allegations around understaffing directly threaten the labor-efficiency assumption embedded in the 8.45% operating margin. If regulators impose staffing mandates, margin could compress 100-200bps. DCF bear case ($199.93) still implies 22.6% upside from current price, providing cushion even in an adverse scenario. The sensitivity range ($199-$298) brackets the current price comfortably on the downside, meaning even a conservative case offers margin of safety. Score: 74 — pass, but confidence is medium due to litigation overhang, stale capex data, high terminal value dependency, and unresolved short-seller allegations that could alter the operating margin story if substantiated.

Key points

Base DCF intrinsic value $258.77 vs. $163.05 price = 58.7% upside; even bear case $199.93 is 22.6% above current price — genuine margin of safety present
ROIC (14.2%) meaningfully exceeds WACC (7.67%), confirming growth is value-creating; low D/E (0.06) validates low-leverage WACC input
Reverse-engineered market price implies only ~6-7% FCF growth — modest, achievable expectation given 18.5% revenue CAGR history; price does not demand perfection
FCF conversion is strong: operating cash flow $564M, Price/FCF 19.3x — reasonable for a growing healthcare operator with demographic tailwinds
12% FCF growth rate used in DCF is conservatively below the 18.5% revenue CAGR, providing a realistic downward buffer on the growth assumption
Terminal value at 81.1% of enterprise value is the primary vulnerability — sensitive to WACC and terminal growth; 2.5% terminal growth is at the high end of defensible
22-year dividend growth streak and $1B+ liquidity dry powder support reinvestment story without balance sheet stress

Red flags

Capex figure ($71.5M) is flagged as from 2019 — stale data likely significantly understates true reinvestment need for a company acquiring 45 operations annually; FCF may be materially overstated
Short-seller (Hunterbrook) allegations of understaffing and metric-gaming, if substantiated, could compress operating margin (currently 8.45%) by 100-200bps under staffing mandates — a direct threat to FCF growth assumptions
Class-action legal probes (Kessler Topaz, Rosen Law) introduce tail risk not captured in the WACC or sensitivity range
Terminal value dependency (81.1%) means the valuation is highly sensitive to terminal growth and WACC inputs; a WACC shift of +100bps or terminal growth of 2.0% instead of 2.5% could move intrinsic value down 15-20%
WACC of 7.67% may be slightly understated post-litigation risk emergence — regulatory risk in SNF sector is non-trivial and sector beta may understate operational leverage
No management rebuttal to short-seller report in available materials — silent response increases uncertainty around whether operating model allegations have merit

Joel Greenblatt — 🟢 pass · 74/100 · medium confidence

Ensign Group passes the Magic Formula screen with reasonably high ROIC and an acceptable earnings yield, though not a screaming bargain on either axis. On the quality side: EBIT of ~$425M on a tangible capital base (net working capital ~$378M + net PP&E — the latter not precisely disclosed in the fact base but implied by total assets of $5.46B less intangibles, goodwill, and lease ROU assets; using operating cash flow and capex as proxies for capital intensity, the business is clearly asset-light in terms of owned hard assets relative to earnings power). ROIC as reported is 14.2%, which is solid for a services business that leases most facilities. The key Greenblatt ROIC denominator (NWC + net fixed assets) is harder to isolate here because ENSG operates heavily via operating leases (SNF facilities), which inflates the balance sheet under ASC 842 but doesn't represent owned productive capital in the classic sense — the true tangible capital employed is likely lower than book equity suggests, meaning true ROIC is understated by standard metrics. On the earnings yield side: EV = market cap (~$9.53B) + LT debt (~$138M) - excess cash (~$504M net cash position; net debt is -$366M per DCF block) = ~$9.16B EV. EBIT/EV = $425M / $9.16B ≈ 4.6%. That is a modest earnings yield — not the 10%+ Magic Formula ideal, but not egregious for a high-quality, consistent compounder. Price/FCF of 19.3x and P/E of 27.7x reflect a premium valuation that partially offsets quality. The DCF intrinsic value of ~$259/share vs. current price of $163 implies ~59% upside, which is meaningful margin of safety IF the 12% FCF growth assumption holds — and the 18.5% revenue CAGR and consistent earnings beats suggest it is defensible. The business is genuinely cash-generative: FCF of $493M on $5B revenue (9.8% FCF margin), operating cash flow $564M, capex only $71M (likely understated for a multi-year period but still capital-light). The decentralized model, 22-year dividend growth streak, and disciplined acquisition strategy reflect owner-like capital allocation. The Hunterbrook short report introduces real regulatory and reputational risk — patient neglect allegations in a Medicare/Medicaid-dependent business are not trivial and could trigger CMS scrutiny, star-rating downgrades, or reimbursement pressure. This is the primary reason I don't score higher. No special-situation catalyst is present; this is a straightforward compounder screen, not a Greenblatt special situation. Net: good business, fair-to-attractive price, meaningful but not exceptional earnings yield, real tail risk from regulatory exposure.

Key points

EBIT/EV earnings yield ~4.6% (EV ~$9.16B net of cash; EBIT $425M) — modest but not expensive for quality
Reported ROIC 14.2%; true tangible-capital ROIC likely higher given lease-heavy model reducing owned fixed assets in denominator
FCF $493M, FCF margin 9.8%, price/FCF 19.3x — genuine cash generation, not accounting mirage
18.5% 3-year revenue CAGR with consistent earnings beats and guidance raises signals durable earnings power
Net cash position ($366M net cash); D/E 0.06 — near-zero leverage risk, EV cheapness is real not illusory
DCF intrinsic value $259 vs. $163 price = 59% upside in base case; bear case $200 still implies 23% upside
Decentralized acquisition model with AIT pipeline and 83% same-store occupancy leaving organic runway without new capex
22-year dividend increase streak and $100M buyback authorization signal management confidence and capital discipline

Red flags

Earnings yield ~4.6% is below Greenblatt's preferred double-digit threshold — not a Magic Formula screamer on cheapness axis
Hunterbrook/Muddy Waters short report alleges patient neglect and metric gaming — CMS regulatory risk is existential for a Medicare/Medicaid-dependent business
Securities class action probes filed (Kessler Topaz, Rosen) — litigation tail risk unquantified
ROIC denominator complicated by ASC 842 lease capitalization — true tangible capital base unclear without full balance sheet detail on goodwill, intangibles, and ROU assets
No special-situation catalyst present — pure compounder thesis, not Greenblatt's highest-conviction setup
Standard Bear REIT subsidiary adds accounting complexity and opacity to consolidated earnings quality assessment
Capex figure ($71M) appears to reference 2019 period — data quality concern; true maintenance capex may differ materially
Stock at 52-week high on day of analysis despite recent 8% short-report drop — no forced-selling discount present

Charlie Munger — 🟢 pass · 74/100 · medium confidence

Ensign Group is a durable, understandable healthcare services business operating skilled nursing facilities (SNFs) and senior living communities. The business model is explicable in a paragraph: acquire underperforming SNFs, install decentralized local leadership, improve clinical quality and occupancy, and hold long-term while demographic tailwinds fill beds. The unit economics are simple — beds, occupancy rates, skilled mix, reimbursement per day. ROIC at 14.18% and ROE at 15.41% sit just at my 15% threshold for quality, trending upward given strong FCF conversion (FCF margin ~9.8%, operating cash flow $564M vs. net income $344M — high earnings quality). Debt is minimal: long-term debt only $137M against $504M cash, net cash positive. Debt/equity 0.06 — essentially unlevered. Revenue CAGR of 18.5% over three years with operating margin expanding is consistent with a business that reinvests at above-average returns via M&A. The DCF suggests ~59% upside to intrinsic value ($258.77 base vs. $163 price), and the bear case ($199.93) still implies meaningful undervaluation — that is a reasonable margin of safety for a quality business. The moat is real but narrow and local: it is not a Coca-Cola brand moat but rather an operational excellence moat built on decentralized management, superior CMS star ratings (24% outperformance), and clinical differentiation creating switching costs with managed care and acute care referral partners. Same-store occupancy at an all-time high of 83% with organic runway to 88% (management's math: equivalent of 8-17 new 100-bed facilities) is powerful and low-capital. Capital allocation has been disciplined — 22-year dividend increase streak, modest M&A pricing discipline, $1B+ dry powder maintained. The serious new risk is the Hunterbrook short-seller report alleging understaffing and patient neglect, paired with class-action legal probes (Kessler Topaz, Rosen Law Firm). This is my primary concern: if the bear thesis that understaffing IS the profit model is substantially correct, the moat narrative collapses and regulatory/reputational risk becomes existential. RBC reiterated its rating post-report, which is modestly reassuring, but no management rebuttal is in the record, and the allegations are unverified. The stock sits at its 52-week low ($163, which equals the high in this data — the 52w high of $218 implies the stock has fallen roughly 25% from peak), indicating the market is discounting meaningful risk. I score this 74: it is a good business at a now-fair-to-cheap price with real organic compounding potential, but the short-seller overhang, unverified regulatory/quality allegations, legal probes, and narrow moat prevent a higher conviction score. I would want to understand the staffing allegations deeply before concentrating. A position makes sense at current levels but demands ongoing vigilance on regulatory and legal developments.

Key points

ROIC 14.2% and ROE 15.4% are at the quality threshold, with FCF of $493M well exceeding net income of $344M — strong earnings quality signal
Near-zero leverage (LTD $137M, net cash +$366M) means the balance sheet survives adversity — inversion test: no obvious path to capital impairment from the balance sheet
Decentralized operational model with 22-year dividend increase streak and disciplined M&A (avoiding Texas 'too rich' deals) reflects owner-minded management
Organic occupancy runway (83% → 88% possible without new fixed overhead) is a rare quality: incremental reinvestment at very high marginal returns
DCF intrinsic value $258.77 base ($199.93 bear) vs. $163 current price offers genuine margin of safety for a quality business — not a cigar butt, a quality business at a fair price
Revenue CAGR 18.5% over three years reflects both M&A and organic improvement, with CMS star rating superiority (24% outperformance) suggesting clinical moat is real

Red flags

Hunterbrook short-seller report alleges understaffing as the core profit driver and patient neglect — if substantially true, this reframes the 'operational excellence moat' as a regulatory and reputational liability
Multiple securities class-action legal probes filed (Kessler Topaz, Rosen Law Firm) as of late June 2026 — litigation risk unquantified and potentially material
No management rebuttal on record to the short-seller allegations — silence is ambiguous and concerning for transparency-minded assessment
Capex figure in fundamentals ($71.5M tagged to 2019) appears mismatched with current period — data quality issue means true owner earnings calculation requires verification
Terminal value represents 81% of DCF intrinsic value, making the $258 estimate highly sensitive to long-run growth and WACC assumptions — moderate sensitivity to being wrong
SNF industry faces persistent reimbursement risk from state Medicaid budgets and federal CMS policy changes; behavioral/regulatory environment could tighten quickly if neglect allegations gain traction

Michael Mauboussin — 🟢 pass · 74/100 · medium confidence

Ensign Group presents a genuinely interesting expectations-investing puzzle. The company earns ROIC of ~14.2% against a WACC of ~7.7%, a spread of roughly 650bps that is meaningful for a healthcare services operator. The DCF implies intrinsic value of ~$259/share vs. current price of $163, suggesting the market is embedding expectations well below management's demonstrated trajectory — creating a potential margin of safety even under base-rate mean-reversion assumptions. The moat source is real but Narrow-to-Moderate: scale economies in regional facility clustering (fixed overhead spread over more beds), meaningful switching costs on the B2B side (hospital discharge planners and managed care partners develop strong workflow dependencies on high-performing SNF operators), and regulatory licenses that create genuine barriers to entry in most states. The CMS 4-5 star rating advantage (+10% vs. peers) and 24% survey outperformance function as a reputational intangible that reinforces referral network stickiness. The acquisition-turnaround model — buying distressed facilities and improving occupancy from ~76% to ~97% over 15 months — is a repeatable skill process, not a single lucky event; the track record across 22+ facilities in 2025 alone, with documented EBIT improvement examples, gives inside-view evidence beyond the base rate. Revenue CAGR of ~18.5% over 3 years with FCF margin of ~9.8% and operating cash flow of $564M against only $71M capex reflects genuine capital-light compounding. The balance sheet is fortress-like: D/E of 0.062, $504M cash, long-term debt of only $137M, net cash position of ~$366M. The 22-year dividend growth streak signals capital discipline. The key uncertainty — and reason I do not score higher — is the Hunterbrook short report alleging understaffing and metric-gaming as the primary profit driver. If the allegations are substantiated, they would challenge the fundamental premise that clinical quality (not labor underfunding) drives the ROIC spread. Regulatory/reimbursement risk and two class-action probes are live tail risks. The DCF is heavily terminal-value-weighted (81% of EV from terminal), which amplifies sensitivity to terminal growth assumptions and means the base case requires sustained 12% FCF growth for 5+ years — achievable given demographics but above the historical base rate for SNF operators. The expectations embedded at $163 appear conservative relative to demonstrated performance, but the short-report uncertainty warrants a watch posture on the franchise-quality question until allegations are resolved.

Key points

ROIC of 14.2% vs WACC of 7.7% — a 650bps spread, meaningful and above the SNF sector base rate, driven by regional clustering scale and referral network switching costs
DCF intrinsic value ~$259/share vs $163 price implies ~37% discount; market appears to be embedding below-trend expectations, creating margin of safety even in bear scenario ($200)
Moat mechanism is real and specific: (1) regional scale economies in facility clusters, (2) CMS star-rating intangible driving referral stickiness — 10% higher 4-5 star share, 24% survey outperformance, (3) managed-care/hospital discharge-planner switching costs on B2B side
Acquisition-turnaround skill appears repeatable, not lucky: multiple documented examples (76%→97% occupancy, EBIT +376%) across diverse geographies; 45 acquisitions in 2025 without ROIC dilution
Organic growth embedded in 83% same-store occupancy (vs. mature comp of mid-90s) represents 650–1,700 equivalent new beds of capacity at zero incremental fixed cost — a powerful earnings option not yet in the price
Balance sheet optionality exceptional: $504M cash, $137M long-term debt, net cash of $366M, $1B+ dry powder — capital allocation discipline evidenced by disciplined M&A walk-away in overpriced markets (Texas cited explicitly)
18.5% revenue CAGR over 3 years with FCF conversion of ~$493M (P/FCF of 19.3x) is attractive for a compounder with these ROIC characteristics
PEG of 1.5 and P/S of 1.89 are undemanding for a franchise compounding at this rate

Red flags

Hunterbrook short-seller report (June 2026) alleges understaffing as the primary profit driver — if true, this reframes the ROIC spread as labor extraction rather than clinical moat, making it regulatory/reputational risk rather than durable competitive advantage
Class-action investigations (Kessler Topaz, Rosen Law) filed as of June 2026 — legal tail risk is live and unresolved; management has not issued a substantive on-record rebuttal in available materials
DCF is 81% terminal-value-dependent — implies extreme sensitivity to terminal growth rate; if growth fades to 2% (vs. assumed 2.5%) or WACC rises 100bps, intrinsic value drops materially; point-estimate confidence in DCF must be tempered
Short report timing coincides with broader SNF sector weakness — industry headwinds (labor cost, Medicaid reimbursement pressure, state budget stress) could amplify reputational damage from allegations beyond the idiosyncratic risk
Standard Bear REIT subsidiary adds accounting complexity; FFO coverage of 2.5x rent is adequate but not wide; opacity in consolidated reporting creates information risk for outside-view ROIC analysis
18.5% revenue CAGR requires sustained high-pace acquisition and execution — acquisition integration risk is real; decentralized model (strength in normal times) creates oversight risk at scale
Operating margin of only 8.45% leaves limited cushion for cost shocks (labor inflation, reimbursement cuts); SNF margins are structurally thin and historically volatile

Ray Dalio — 🟢 pass · 72/100 · medium confidence

ENSG is a skilled nursing facility (SNF) operator with essentially government-mandated, non-discretionary demand — the demographic engine is independent of the credit cycle. From a Dalio regime lens, the critical test is how earnings behave across the four boxes. Healthcare services (Medicare/Medicaid-funded SNF) is one of the more regime-robust sectors: in deflationary bust, demand is sticky and government reimbursement sustains revenue; in stagflation, labor costs rise but Medicare annual market basket updates (confirmed +3.2% Oct 2025) provide partial pass-through and occupancy holds because hospitalization overflow and elderly demand doesn't compress; in boom/rising growth, occupancy fills faster and skilled-mix improves margin. The weakest regime is probably inflationary with rate spikes that ENSG partially sidesteps because its balance sheet is extraordinarily clean. Net debt/EBITDA of ~1.86x (management) and long-term debt of only $137.5M against $503.9M cash (net cash position of ~$366M) means refinancing risk is nearly zero. The company is essentially self-funding with $492.7M in FCF against modest capex. This is highly unusual for a healthcare facility operator and provides meaningful balance-sheet resilience. Rate sensitivity of the OPERATING business is low since ENSG owns few properties directly (Standard Bear REIT subsidiary holds properties, creating some lease obligations off the operating entity). The REIT subsidiary adds some complexity — 2.5x EBITDAAR/rent coverage is adequate but not lavish; a severe occupancy downturn could pressure coverage. Key risks under the Dalio framework: (1) regulatory/reimbursement risk from government as primary payor — in a fiscal consolidation scenario (deflationary deleveraging with government austerity), Medicare/Medicaid rates could be cut, which would compress margins directly since ENSG cannot easily replace government revenue with private-pay; (2) the Hunterbrook short report alleging understaffing introduces a regulatory tail risk that could accelerate government scrutiny — this is a non-macro but material risk; (3) labor cost inflation is the primary operating risk — wages are 60-70% of SNF cost structures, and if wage inflation outpaces reimbursement rate increases, margins compress (partial stagflation vulnerability); (4) geographic concentration is entirely U.S. domestic with no FX diversification, which adds reserve-currency concentration risk. Valuation at 19.3x FCF and a DCF implying 59% upside ($258.77 intrinsic vs. $163 market price) provides a decent margin of safety against a regime shift — the stock is not priced for perfection. The strong FCF yield (~4.6% earnings yield on P/E, ~5.2% FCF yield implied by price/FCF of 19.3x) is reasonable for a regime-resilient operator. Demographically driven demand with minimal credit-cycle linkage is exactly the kind of uncorrelated-to-credit-cycle exposure that adds diversification value to a broad equity book.

Key points

Regime robustness: Medicare/Medicaid revenue (~majority of mix) is non-cyclical; SNF demand is non-discretionary and driven by demographics, not credit availability — survives deflationary bust and stagflation better than most sectors
Balance sheet fortress: net cash position of $366M ($503.9M cash vs. $137.5M LT debt), net debt/EBITDA well below 2x; can fund operations and acquisitions through a credit freeze without capital market access
Self-funding FCF: $492.7M operating FCF vs. $71.5M capex (note: capex figure may be 2019 vintage — filing data gap) generates substantial internal capital for reinvestment and buybacks ($100M authorization)
Inflation partial pass-through: Annual Medicare market basket adjustments (+3.2% Oct 2025) provide built-in but lagging inflation protection; labor is primary cost risk but managed care mix growing (+7-24% revenue YoY) adds pricing optionality
Demographic tailwind uncorrelated to macro: 80+ population +50% by 2035 is a structural demand driver independent of economic cycle, providing long-duration cash flow visibility
DCF margin of safety: intrinsic $258.77 vs. $163 market price (59% upside) with bear case $199.93 — provides cushion against regime shift repricing
Low correlation value: SNF operating cash flows driven by regulatory reimbursement, staffing, and demographics — genuinely different return drivers from typical equity/credit book

Red flags

Government reimbursement dependency (single-payor tail risk): in a fiscal austerity/deleveraging scenario, CMS could cut Medicare/Medicaid rates — the company cannot substitute private-pay at scale; this is the primary regime vulnerability
Hunterbrook short report (June 8, 2026) alleging understaffing and patient neglect introduces regulatory investigation risk — if substantiated, could trigger survey failures, reimbursement restrictions, or civil penalties that stress FCF materially
Labor cost inflation risk: wages represent the dominant cost structure for SNFs; if wage inflation (particularly minimum wage legislation at state level) outpaces annual reimbursement updates, margins compress in a stagflationary regime
Standard Bear REIT subsidiary complexity: 2.5x EBITDAAR/rent coverage provides limited buffer; in a severe occupancy downturn, lease obligations become a fixed-cost drag; off-balance-sheet lease liabilities add implicit leverage not captured in stated LT debt
100% U.S. domestic revenue: zero geographic diversification means full exposure to domestic fiscal policy, regulatory risk, and USD as reserve currency — no natural hedge to a dollar depreciation scenario
Capex data anomaly in fact base (2019 period listed for capex): if true capex is materially higher than $71.5M reported, FCF and valuation metrics would be overstated — data gap reduces confidence
Class-action lawsuits filed (Kessler Topaz, Rosen Law): litigation risk in early stages but creates overhang and potential settlement costs

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

Ensign Group operates skilled nursing facilities (SNFs) and senior living communities — physical care delivery for elderly, medically complex, often post-acute patients. The core 'job' this company does is providing hands-on clinical and custodial care: wound management, physical therapy, IV therapy, dementia care, feeding assistance, ambulation, and complex medication management in a licensed, regulated physical environment. AI cannot replace the human hands doing this work. The obsolescence question has a clear answer: no AI model can bathe a patient, reposition a bed-bound resident to prevent pressure ulcers, or administer a feeding tube. This is among the most AI-disruption-resistant business models in the economy — the value delivered is irreducibly physical labor in a licensed facility. The disintermediation risk is essentially nil: ENSG is not a matching intermediary or digital toll-taker between two parties; it IS the care provider. There is no third party that AI could route patients around ENSG to reach. On the cost side, AI offers real but limited tailwinds: scheduling optimization (reducing agency labor costs, which management says is already improving), clinical documentation automation (reducing nursing administrative burden), early-warning systems for sepsis or readmission risk, and care-plan generation. These could modestly improve margins over the 3-10 year horizon, but they are incremental, not transformational. The labor-intensity of SNF care (staffing is ~60-70% of costs) means AI tools that reduce documentation time or improve scheduling could save meaningful dollars — management noted agency usage declining, which likely reflects some operational improvement. However, the Hunterbrook short report alleges that ENSG's profitability is driven by understaffing, which if true, means the 'AI as efficiency tool' framing may already be stretched. The more interesting AI risk is second-order: if AI-enabled remote monitoring and hospital-at-home models reduce post-acute SNF utilization by keeping patients out of facilities longer or recovering at home, that is a meaningful demand-side threat over the 10-year horizon. Programs like remote patient monitoring, AI-triage that routes lower-acuity patients to home health rather than SNF, and hospital-at-home expansions (Amazon, Best Buy, major health systems all investing) could compress SNF admission volumes at the margin. Management's own bull case — 83% occupancy growing to 88% driven by demographics — could be partially offset by care-setting substitution. This is real but not existential: the most medically complex, functionally dependent 80+ patients require institutional care regardless. AI-native competitors are not a threat: building and operating a SNF requires state licensure, CON (certificate of need) in some states, Medicare/Medicaid certification, physical plant, and a trained clinical workforce. Google cannot open a nursing home. Management's earnings call framing treats AI as a background operational tool (staffing, documentation) rather than a strategic theme — this is honest given their business model, not denial. They name labor efficiency as a real lever. The short-seller allegations of metric-gaming and understaffing create an indirect AI-era risk: regulators increasingly use data analytics and CMS quality metrics to identify poor performers, and if AI-driven regulatory surveillance (CMS uses algorithmic screening for audit targeting) identifies ENSG facilities as outliers, that is a compliance risk amplified by AI — but this is a corporate governance risk, not a disruption risk per se. Overall: ENSG is a physical-care incumbent in a sector with essentially no disintermediation risk, meaningful AI tailwinds on the cost side, and a modest but real demand-side risk from care-setting substitution over the 10-year horizon. Score 72 — a clear pass on the disruption lens, with the main watch item being hospital-at-home/remote monitoring reducing SNF admissions for borderline-acuity patients.

Key points

Core job is irreducibly physical hands-on care — AI cannot substitute for bathing, wound care, ambulation, or complex medication administration in an institutional setting
No disintermediation risk: ENSG is the care provider, not a matching intermediary; no third party can be routed around them
AI cost-side tailwinds are real: scheduling optimization, clinical documentation automation, early-warning clinical systems could improve margins modestly over 3-10 years
Demographic tailwind (80+ population +50% by 2035) is largely AI-resistant demand — severe functional dependence requires institutional care regardless of technology
No AI-native competitor can enter SNF care: requires state licensure, Medicare/Medicaid certification, physical plant, and clinical workforce — structural barriers AI cannot dissolve
Regulatory AI surveillance (CMS algorithmic audit targeting) could amplify compliance risk if understaffing allegations have merit — indirect risk, not disruption risk

Red flags

Hospital-at-home and remote patient monitoring, backed by Amazon/Best Buy/major health systems with AI triage, could divert lower-acuity post-acute patients away from SNFs over a 10-year horizon — real but partial demand-side threat
If AI-driven care-setting optimization by payers (managed care, Medicare Advantage plans) routes borderline patients to home health instead of SNF, ENSG's skilled-day revenue growth thesis faces a structural headwind
Hunterbrook allegations of metric-gaming are precisely the kind of data-quality issue that AI-enhanced CMS surveillance could surface at scale, amplifying regulatory scrutiny risk — though this is governance, not disruption
Management does not engage with the hospital-at-home/care-substitution risk in the Q3 2025 call — a gap in their AI/disruption disclosure, though understandable given business model

Chuck Akre — 🟡 watch · 62/100 · medium confidence

Ensign Group has two of Akre's three stool legs firmly in place — a genuinely good business with a disciplined reinvestment runway — but the third leg (management integrity) now has a crack that cannot be dismissed. The business economics are real: $492.7M in FCF on $5.03B revenue yields a 9.8% FCF margin and the FCF converts well from operating income ($425M operating income vs $564M OCF shows minimal accrual manipulation). ROIC of 14.2% and ROE of 15.4% are solid and achieved on very modest leverage (debt/equity 0.06x, long-term debt only $137.5M vs $2.23B equity) — so returns are genuine, not financial-engineering artifacts. The reinvestment runway is arguably Ensign's strongest leg: 83% same-store occupancy with documented runway to 88%+ (equivalent to 8–17 new 100-bed facilities of free capacity), a 73-acquisition pipeline since 2024, and the 80+ U.S. population growing 50% by 2035. Management has a 22-year dividend growth streak, demonstrated acquisition discipline (avoiding overpriced Texas deals), and a decentralized operator model that Akre would recognize as a scalable, culture-driven franchise. The capital allocation track record — $240M+ deployed in 2025, sensible M&A transforms facilities from sub-75% to 95%+ occupancy, net debt/EBITDA only 1.86x — is largely admirable. However, the Hunterbrook short-seller report alleging understaffing, patient neglect, and metric-gaming represents a direct integrity flag that Akre takes very seriously. The bear thesis that 'understaffing IS the profit model' — if substantiated — would mean the reported returns on capital rest on a foundation Akre would find disqualifying: exploiting a regulatory gap and vulnerable patients rather than genuine operational excellence. RBC reiterated its rating, but two separate class-action law firms have opened probes. Management's silence (no public rebuttal in the material) is noted. On valuation: the DCF at $258.77/share vs. $163.05 current price (59% upside) uses a 12% FCF growth rate consistent with the revenue CAGR and a 7.67% WACC — reasonable assumptions for this quality tier. At P/FCF of 19.3x and PE of 27.7x with a PEG of 1.5, the price is not obviously cheap but is not stretched for a compounder of this quality IF the integrity concerns resolve cleanly. The capex figure of $71.5M appears dated (labeled 2019-12-31 in the data), creating uncertainty in true normalized FCF — this missing data reduces confidence. On balance: a business Akre would admire structurally, with management he would need to trust but currently cannot fully, at a price that is reasonable but not a bargain. The integrity cloud is the swing factor.

Key points

FCF of $492.7M (9.8% margin) converts cleanly from operating income — no accrual-inflation artifacts; strong cash conversion is Akre's primary screen
ROIC 14.2% / ROE 15.4% achieved on minimal leverage (D/E 0.06x, LT debt only $137.5M) — returns are genuine business economics, not financial engineering
Reinvestment runway is exceptional: 83% same-store occupancy with 5–8pp headroom, 73+ acquisitions since 2024, 50% growth in 80+ U.S. population by 2035 — the most important Akre leg is intact
Revenue CAGR of 18.5% over 3 years with per-share FCF growing demonstrates compounding in action, not just top-line growth
Decentralized operator model, 22-year dividend growth streak, disciplined M&A (avoiding overpriced Texas market) reflect the capital allocation discipline Akre prizes
DCF intrinsic value ~$259/share vs $163 current price implies ~59% upside — reasonable valuation for a true compounder at 7.67% WACC and 12% growth; P/FCF 19.3x is not stretched for this quality
$1B+ liquidity ($593M credit + $444M cash), net debt/EBITDA 1.86x — fortress balance sheet enables opportunistic acquisitions without dilution

Red flags

Hunterbrook short-seller report (June 8, 2026) alleges understaffing and patient neglect as the core profit driver — if true, this would mean returns rest on regulatory arbitrage rather than genuine excellence, a direct Akre integrity disqualifier
Two securities class-action law firms (Kessler Topaz, Rosen Law) have opened formal probes as of late June 2026 — legal/regulatory tail risk is now non-trivial
Management has not publicly rebutted the allegations in available material; silence could signal either confidence or avoidance — Akre requires candid shareholder communication
Capex data labeled '2019-12-31' in the fundamentals block — normalized maintenance capex is unclear, making true owner earnings uncertain; this is a data quality flag that reduces confidence in FCF assessment
Operating margin of 8.45% is serviceable but not the high-margin franchise Akre typically prizes (he prefers 20%+ operating margins); care facilities are inherently labor-intensive with limited pricing power beyond government reimbursement rates
SNF sector reimbursement risk: revenue mix heavily tied to Medicare/Medicaid, creating policy/regulatory dependency that can compress margins without operational fault — limits pricing power dimension of Akre's moat framework
Stock is trading at 52-week high ($163.05 = 52w high per price block) immediately post-8% short-report selloff, suggesting the pre-report price was ~$177+; the market had priced in more optimism, which has been partially deflated

Warren Buffett — 🟡 watch · 62/100 · medium confidence

Ensign Group is a legitimate, profitable, and understandable business operating skilled nursing and senior living facilities — squarely within a circle of competence I can evaluate. The economics are straightforward: acquire underperforming SNF facilities, apply a decentralized operational model to improve occupancy and skilled mix, and benefit from demographic tailwinds as the 80+ population grows. The business has genuine strengths: 18.5% revenue CAGR over three years, ROIC of 14.2%, ROE of 15.4%, a remarkably clean balance sheet (debt-to-equity of 0.06, net cash position of ~$366M), strong FCF conversion ($493M FCF on $344M net income, meaning D&A and working capital dynamics are favorable), and 22 consecutive years of dividend increases — a hallmark of consistent, honest capital allocation. The two-stage DCF pegs intrinsic value at ~$259/share versus a $163 current price, suggesting meaningful upside if the model is correct. However, several issues temper my enthusiasm. First, the Hunterbrook short-seller report alleging understaffing and patient neglect introduces material regulatory, reputational, and legal risk — class-action probes are now filed, and while I treat short reports skeptically, understaffing in a Medicare/Medicaid-regulated environment can trigger survey failures, reimbursement cuts, and facility closures, all of which are existential threats to individual operating units. Management has not publicly rebutted these allegations in any material I can review. Second, the moat is debatable. SNF operators face regulatory caprice, labor market exposure, and reimbursement dependence on government payers — not classic pricing power. Ensign's CMS 4-5 star rating advantage (10% above peers) and same-store occupancy highs (83%) suggest operational differentiation, but this is an execution moat, not a structural one, and it requires constant reinvestment in clinical talent and management culture. Third, operating margins at 8.5% are thin and compress quickly if labor costs rise or reimbursement rates disappoint. Fourth, the acquisition-driven growth model — 45 operations added in 2025 alone — introduces integration risk and accounting complexity, and the Standard Bear REIT subsidiary adds opacity I find uncomfortable. The DCF's 81% terminal value weighting means today's price is almost entirely a bet on long-duration growth at 12%/year — aggressive for a regulated healthcare operator. At $163 (off the 52-week high of $218, with the 52-week data showing the close AT the 52-week low as listed, which seems inconsistent — the data shows both high and low as $163.05 which appears to be a data artifact; the narrative references a prior high of $218 and the 52-week low of $134.79 separately), there may be a margin of safety if the short-seller allegations are without merit and growth continues. But I want more clarity on the regulatory exposure before committing fully.

Key points

ROE of 15.4% and ROIC of 14.2% achieved with minimal leverage (D/E of 0.06, net cash balance sheet) — rare and attractive combination
Strong owner earnings: $493M FCF vs $344M net income indicates high-quality earnings with real cash conversion; price-to-FCF of 19.3x is reasonable for the growth rate
22-year consecutive dividend increase streak signals honest, long-term oriented capital allocation; $40-100M buyback authorized
Revenue CAGR of 18.5% over 3 years with same-store occupancy at all-time highs (83%) and documented turnaround track record (occupancy 76%→97% at example facilities)
DCF intrinsic value ~$259/share offers ~59% upside at $163 — significant margin of safety IF growth assumptions hold
Demographic tailwind is genuine and multi-decade: U.S. 80+ population growing ~50% by 2035
Decentralized operational model with deep bench of trained facility leaders is a repeatable, culture-embedded advantage that is difficult to replicate quickly

Red flags

Hunterbrook short-seller report (June 2026) alleging understaffing and patient neglect — if substantiated, could trigger CMS sanctions, reimbursement loss, or facility shutdowns; class-action legal probes now active (Kessler Topaz, Rosen Law)
No management rebuttal on record in available materials — silence on serious allegations is concerning
Regulatory dependence: Medicare/Medicaid payers represent the vast majority of revenue; government reimbursement rate changes or survey failures can impair economics with little warning
Thin operating margins (~8.5%) leave limited buffer if labor costs rise or skilled mix deteriorates — not the wide-moat economics I prefer
Acquisition pace (45 new operations in 2025) introduces integration risk and dilutes management bandwidth; Standard Bear REIT subsidiary adds accounting complexity and opacity
DCF is 81% terminal value — essentially pricing long-duration 12% FCF growth; any slowdown in skilled mix improvement or regulatory headwind collapses the thesis
Capex data inconsistency in fact base (capex period listed as 2019) — signals potential data quality issue; maintenance vs. growth capex split not clearly disclosed

Bruce Greenwald — 🟡 watch · 62/100 · medium confidence

Ensign Group is a legitimate target for EPV analysis given its operating history, real earnings, and identifiable asset base. My core framework requires me to establish: (1) normalized earnings power, (2) asset reproduction value, and (3) whether EPV materially exceeds reproduction value — which is the moat test. Working through each: EPV estimate: Operating income (2025) = $425M, tax-affect at ~24% effective rate → NOPAT ≈ $323M. Capex figure in the fact base is anomalous ($71.5M dated 2019-12-31 — clearly stale/mismatched), so I must use operating cash flow minus the disclosed FCF figure to back-infer capex: OCF $564M - FCF $493M = ~$71M maintenance+growth capex total. Given the acquisition-heavy model, true maintenance capex is likely lower; I'll conservatively assume $50M maintenance. Adjusted distributable earnings ≈ NOPAT + excess D&A ≈ $323M. At WACC 7.67%, EPV ≈ $323M / 0.0767 ≈ $4.21B enterprise value. Add net cash of ~$366M → equity EPV ≈ $4.58B, or roughly $78/share. The market pays $163/share — roughly 2.1x my EPV. Asset reproduction value: Total assets $5.46B, total liabilities $3.23B — book equity $2.23B. But skilled nursing facilities carry enormous intangible value in licenses, certificates of need (CONs), established state relationships, and a trained operator pipeline that is genuinely difficult to replicate. Reproduction value of tangible assets alone is probably $2.2–2.8B equity. The 22-year acquisition track record, AIT leadership pipeline, and decentralized operating model are real intangibles — perhaps worth $500M-$1B more in reproduction terms. Call reproduction equity value $2.7–3.5B, or $46–$60/share. The gap: EPV ($78/share) >> reproduction value ($46–60/share) — this is consistent with a real franchise: customer captivity from CON-protected geographies, scale efficiencies within regional clusters, and Medicare/Medicaid relationships that generate above-cost-of-capital returns. ROIC of 14.2% versus WACC of 7.7% confirms excess returns. The moat appears real. The problem: The market price of $163 is 2.1x EPV and 2.7–3.5x reproduction value. This gap can only be rationalized by growth — specifically, the organic occupancy ramp (83% → 88%) plus continued acquisition-fueled expansion. I am deeply skeptical of paying this price: my discipline says growth creates value ONLY inside a verified moat, and even then I should not pay for it speculatively. The current price embeds ~18.4% EPS CAGR continuation, which the provided DCF's 81% terminal-value weight confirms is essentially a bet on perpetual above-average growth. The Hunterbrook short-seller allegations (understaffing, metric gaming, patient neglect) introduce material tail risk — if regulatory scrutiny leads to staffing mandates or reimbursement clawbacks, normalized earnings could drop sharply and my EPV collapses further. RBC's reiteration is reassuring but institutional analysts are not EPV practitioners. The class-action probes add legal cost uncertainty. On the other hand, the decentralized operator model is genuinely differentiated, CON barriers are real, and management's 22-year track record is not nothing. The business earns well above cost of capital and the moat test passes — I simply cannot pay 2x EPV even for a franchise. A price closer to $90–110 (15–40% premium to EPV, reflecting intangible franchise value) would attract serious interest.

Key points

EPV estimated at ~$78/share (NOPAT ~$323M capitalized at WACC 7.67%) — market price of $163 is ~2.1x EPV, requiring substantial growth to be value-accretive
EPV >> reproduction value ($46–60/share) confirms a real franchise: CON-protected geographies, decentralized operator pipeline, Medicare/Medicaid relationships generate ROIC of 14.2% vs WACC of 7.7%
Moat test passes: customer captivity through CON barriers, regional scale economies, and 22-year acquisition/operating track record are genuine barriers to entry
However, at $163 the entire valuation is growth-dependent — DCF terminal value represents 81% of enterprise value, exactly the speculative long-horizon dependence I distrust
Organic occupancy story (83% → 85–88%) is plausible and margin-accretive if delivered; acquisition pipeline shows discipline; these are real options but I do not pay for options at 2x EPV
Capex data in fact base is clearly stale (2019 figure) — earnings normalization is hampered; true maintenance capex unknown, making EPV range wide

Red flags

Market price ~2.1x EPV — gap requires optimistic growth to be justified, violating my core discipline of not paying for growth above EPV
Hunterbrook allegations (understaffing, patient neglect, metric gaming) could compress normalized earnings if staffing mandates or reimbursement clawbacks materialize — EPV is not stress-tested for this
Class-action securities probes (Kessler Topaz, Rosen Law) introduce legal cost and distraction risk not reflected in my normalized earnings estimate
Stale capex data (2019 figure used in fundamentals block) makes earnings normalization unreliable — I cannot precisely calibrate maintenance vs. growth capex
DCF terminal value = 81% of enterprise value — this is precisely the long-horizon speculation I distrust; the provided intrinsic value of $258 is not my anchor
Acquisition-heavy model means reported earnings mix organic and turnaround contributions, making cycle-normalized earnings power genuinely hard to isolate

Philip Fisher — 🟡 watch · 58/100 · medium confidence

Ensign Group presents a genuinely interesting case through the Fisher lens, but ultimately sits in ambiguous territory. The company demonstrates several Fisher-positive attributes: an 18.5% revenue CAGR over 3 years, consistent occupancy gains driven by organic improvement (83% same-store at all-time high with credible runway to 85-88%), strong decentralized management culture with a deep bench of locally-empowered operators, disciplined capital allocation, and a powerful long-term demographic tailwind (80+ population +50% by 2035). These are real Fisher-quality signals. However, the core growth engine is acquisition-driven serial rollup rather than the organic product/market expansion Fisher prized. Revenue CAGR of 18.5% overstates true organic growth — management's own Q3 call notes 22 acquisitions closed just in Q3 plus since, and 45 total in 2025, with acquired ops contributing 15.5%+ of Q3 revenue. Same-store organic growth (5.1% skilled days, ~10% Medicare revenue) is solid but not exceptional. There is no meaningful R&D pipeline — this is a services business with no product innovation dimension, which is a fundamental mismatch with Fisher's framework. The Hunterbrook short-seller report alleging understaffing and patient neglect strikes at Point 14/15 integrity concerns: management has not publicly rebutted allegations, class-action probes are now filed, and the bear thesis that understaffing IS the profit model is corroborated by retail discussion participants with industry knowledge. Operating margins of 8.45% are modest and not clearly above best-in-class peers. The decentralized 'AIT pipeline' model and management bench depth are genuine Fisher positives — the earnings call shows substantive, candid, non-promotional communication with specific facility-level examples and honest commentary on deal pricing discipline. The 22-year dividend streak and buyback expansion show shareholder orientation, though Fisher preferred internal reinvestment over dividends. The short-seller cloud materially impairs scuttlebutt confidence in clinical quality claims.

Key points

Revenue CAGR 18.5% over 3 years is impressive but primarily acquisition-driven; same-store organic growth (~5-10% in key metrics) is solid but not Fisher-tier exceptional
Decentralized leadership model with deep AIT bench represents genuine management depth Fisher would respect — not a one-man operation
Strong demographic tailwind (80+ population +50% by 2035) provides credible multi-year secular runway analogous to Fisher's preferred expanding-market criterion
Organic occupancy runway: 83% same-store with management quantifying path to 85-88% as equivalent to 8-17 new 100-bed facilities without new fixed overhead — this is genuine organic leverage
Management candor on deal pricing discipline (walking away from Texas deals, acknowledging 'capital flooding in') scores well on Fisher's integrity criteria
Free cash flow $492.7M, FCF margin 9.8%, ROIC 14.2% — respectable capital efficiency but not elite
22-year dividend growth streak and $100M buyback authorized signal financial confidence; Fisher would prefer heavier internal reinvestment

Red flags

No R&D pipeline — fundamental structural mismatch with Fisher's framework; growth is operational/geographic rather than product/technology
Hunterbrook short-seller report alleging understaffing and patient neglect directly undermines Fisher's scuttlebutt method — if clinical quality is the stated moat but understaffing is the actual profit driver, the competitive differentiation narrative is suspect
Management silence on Hunterbrook allegations violates Fisher's candor criteria (Points 14/15); no rebuttal in available materials; class-action probes (Kessler Topaz, Rosen Law) now formally filed
Serial acquisition dependence: 45 acquisitions in 2025 alone makes it difficult to isolate true organic earnings power; Fisher was skeptical of rollups as a long-term compounder
Operating margin 8.45% is modest and not clearly superior to best SNF peers — margin protection through scale not demonstrated convincingly
Short-termism risk: if understaffing allegations are substantiated, the cost discipline that drives margins may come at the expense of long-term franchise value and regulatory standing

Peter Lynch — 🟡 watch · 58/100 · medium confidence

ENSG is best categorized as a stalwart-to-fast-grower hybrid — a skilled nursing facility operator running a disciplined roll-up/turnaround formula with genuine organic growth optionality. Revenue CAGR of 18.5% over 3 years and ~18% adjusted EPS growth (Q3 2025 call: +18% YoY adjusted EPS) push it toward fast grower territory, which is where the Lynch framework gets excited. The repeatable formula is real and explainable in a sentence: buy underperforming SNFs cheap, install local leadership, drive occupancy from 76% toward 95%, improve skilled mix, repeat across 40+ states. That is a classic Lynch roll-out story. BUT the PEG is the dealbreaker right now. At P/E 27.7x with EPS growth around 18% (using the guided ~18% YoY adjusted figure), the PEG lands at roughly 1.5 — well above my 1.0 threshold and meaningfully above the 0.5 'excellent' level. The stated PEG of 1.5 in the fact base confirms this. Adding the tiny dividend yield ($0.26/year annualized, ~0.16% yield) barely moves the needle. A stalwart I'd expect to buy at PEG 0.5–0.8; a fast grower at PEG 0.75–1.0. At 1.5, I'm overpaying for what is undeniably a good business. Balance sheet is excellent — debt/equity of 0.06, $504M cash, net cash positive (~$366M net cash per the DCF assumptions), long-term debt only $137M against $5B revenue. That's fortress-level and removes the debt red flag entirely. Free cash flow of $493M on a $9.5B market cap gives price/FCF of 19.3x — acceptable but not cheap for the category. Operating margin at 8.5% is thin for a healthcare operator (SNF economics are structurally challenged), though FCF conversion is strong. The Hunterbrook short-seller report (June 2026) alleging understaffing and patient neglect introduces a serious wildcard. I don't dismiss short sellers — sometimes they're right. The allegations that understaffing IS the profit model is exactly what a Lynch investor needs to investigate before owning; if true, it's not a durable competitive advantage, it's regulatory and reputational risk with a ticking clock. RBC reiterated, lawyers filed class-action probes, and the company responded with buyback expansion ($40M→$100M) — a 'no response response' per retail commentary. Management silence on specifics is concerning. The DCF shows 59% upside to intrinsic value ($258 vs $163), which is compelling if the earnings story holds. But at a 12% assumed FCF growth rate over 5 years against an 18% recent CAGR, the DCF may actually be conservative — or the short-report allegations could compress earnings if staffing costs must rise to meet regulatory standards. The organic occupancy runway (83% same-store, room to 88%+ without M&A) is genuinely exciting Lynch material — that's 8-17 free 100-bed facility equivalents of embedded growth. Same-store skilled mix at only 31.7% of days is a large opportunity. I like the story, I understand the business, and the balance sheet is clean. I just can't get excited at PEG 1.5 with a live short-seller allegation on the core profit driver unresolved. This is a watch — buy on a pullback to ~$120–$135 (PEG closer to 1.0) or after the Hunterbrook allegations are definitively rebutted.

Key points

Repeatable Lynch roll-out formula: buy underperforming SNFs, install local leadership, drive occupancy from ~76% to 95%+ — same explainable unit-economics story that made great stalwart/fast-grower investments
Revenue 3-year CAGR 18.5%; adjusted EPS +18% YoY (Q3 2025); same-store occupancy at all-time high 83% with stated runway to 88%+ = organic growth equivalent to 8-17 new 100-bed facilities without new fixed overhead
Balance sheet is exceptional: D/E 0.06, net cash ~$366M, LT debt only $137M, $493M FCF — self-funding growth story with no debt risk
DCF intrinsic value $258.77 vs $163.05 price = 59% upside in base case; bear case still $200, implying meaningful margin of safety on valuation
$40M→$100M buyback authorization while stock is ~25% below 52-week high ($218) signals management conviction; 22-year dividend growth streak shows capital discipline
Demographic tailwind unambiguous: 80+ U.S. population +50% by 2035; 40% declining dependency ratio — secular demand story Lynch would find compelling

Red flags

PEG of ~1.5 (stated in fundamentals; confirmed by P/E 27.7x / ~18% growth) — materially above the 1.0 Lynch threshold; overpaying even for a good business
Hunterbrook short-seller report (June 8, 2026) alleges understaffing as core profit mechanism and patient neglect — if even partially true, this is an existential threat to the regulatory license-to-operate and the quality differentiation narrative management relies on
Securities class-action probes filed (Kessler Topaz, Rosen Law) — legal overhang creates real uncertainty; management issued no substantive public rebuttal as of the fact base date
Stock trading at 52-week high ($163 = high) with 25% below former $218 high — not the neglected, unloved Lynch name; substantial institutional ownership likely given $9.5B market cap
Operating margin only 8.5% — thin for healthcare; any mandatory staffing cost increases (regulatory response to neglect allegations) could compress margins significantly and break the earnings growth story
REIT subsidiary (Standard Bear) adds balance-sheet and accounting complexity that makes the consolidated story harder to explain cleanly — Lynch prefers simplicity

Howard Marks — 🟡 watch · 55/100 · medium confidence

ENSG presents a genuinely mixed picture through the Howard Marks lens. On the positive side, the stock has pulled back materially from its 52-week high of $218 to ~$163 (a 25% decline), the DCF model suggests ~59% upside to intrinsic value of $258.77, and the balance sheet is genuinely conservative — debt/equity of 0.062, net cash position of ~$366M, current ratio 1.42, and operating cash flow of $564M against long-term debt of only $137M. These structural facts are real and verifiable. The short-seller (Hunterbrook, Muddy Waters referenced) report has injected fear and forced some selling, which is exactly the kind of sentiment environment Marks rewards when the underlying value is intact. However, from a second-level thinking perspective, the situation is not clean enough to rate as a strong contrarian buy. The allegations of understaffing, patient neglect, and metric-gaming are unresolved — if even partially true, they represent regulatory/reimbursement risk that could impair the FCF on which the DCF is premised. Class-action probes (Kessler Topaz, Rosen Law) are in play, adding tail-risk. The current price at 27.7x earnings and 19.3x FCF is not a beaten-down, priced-for-catastrophe valuation — it is a quality-growth multiple that embeds continued execution. The PEG of 1.5 is not cheap by any distressed or deep-value standard. The DCF's 81% terminal value dependency means the intrinsic value is heavily sensitive to assumptions about long-run growth and WACC; a modest deterioration in reimbursement or occupancy rates could compress the terminal value sharply. Sentiment is negative but not at capitulation; retail chatter is cautious rather than revulsed. The organic growth story (83% same-store occupancy, demographic tailwind) and decentralized model are credible first-level bull cases — not a variant view. The stock is not priced for catastrophe, but it is no longer priced for perfection either, which makes it a 'watch' rather than a clear contrarian opportunity or a clear avoid.

Key points

Balance sheet is genuinely fortress-like: net cash ~$366M, LTD only $137M, D/E 0.062, current ratio 1.42 — this is real structural resilience that limits permanent-loss risk
DCF implies ~59% upside to $258.77 intrinsic value; bear case of $199.93 still suggests ~23% upside even in adverse scenario, providing a cushion
Stock has declined ~25% from 52-week high of $218 to $163 — fear is in the price, but not at panic levels; this is a partial, not full, sentiment wash
FCF yield of ~5.2% (price-to-FCF 19.3x) and earnings yield of 4.6% are modest but not cheap on an absolute basis for a healthcare operator with regulatory exposure
Revenue CAGR of 18.5% over 3 years and 18+% adjusted EPS growth are impressive, but the question is what multiple the market should pay for this growth given newly surfaced operational risk
Buyback expansion to $100M signals management confidence, but at ~1% of market cap it is a modest signal rather than a transformative capital return

Red flags

Hunterbrook short-seller report alleging understaffing, patient neglect, and metric-gaming remains unresolved — if even partially substantiated, it could trigger CMS star-rating downgrades, reimbursement clawbacks, or labor cost step-ups that impair the FCF base used in DCF
Class-action securities probes (Kessler Topaz, Rosen Law) represent tail-risk; legal costs and settlement potential are unknown but material for a $9.5B market cap company
DCF terminal value represents 81% of total equity value — this extreme back-loading means the model is extremely sensitive to long-run growth and WACC assumptions; any regulatory or demographic miss compounds heavily
Valuation is not distressed: P/E 27.7x, price-to-FCF 19.3x, P/B 4.27x — these are quality-growth multiples that embed continued execution, not beaten-down multiples that price in bad news
Sentiment has turned negative but has not reached revulsion or forced-selling panic; institutional holders have not demonstrably capitulated; the bar for a Marks-style contrarian entry has not been fully cleared
The bear thesis (understaffing as sole profit driver) is structurally coherent with the company's stated efficiency-focused model — management's own language around 'lean operations' could be weaponized in litigation or regulatory proceedings

Terry Smith (Fundsmith) — 🟡 watch · 55/100 · medium confidence

Ensign Group is an established, profitable, cash-generative healthcare services business — my quality screen can be applied. However, it falls short of the Fundsmith quality bar on several key dimensions. Starting with what I like: FCF conversion is excellent ($493M FCF vs $344M net income, meaning FCF exceeds net income — a strong signal of earnings quality with no accrual flattery). Capital intensity is genuinely light: capex of $71M against $564M operating cash flow yields a FCF margin of ~9.8%, and the asset-light character is reinforced by the operating model. Debt/equity is only 0.06x, and the balance sheet is net cash positive ($504M cash vs $138M long-term debt, net cash of ~$366M) — so leverage is not a concern, which is rare in healthcare services. Revenue CAGR of 18.5% over three years with consistent earnings beats and a 22-year dividend growth streak all point to disciplined capital allocation.

However, my primary concern is ROCE. ROIC of 14.2% and ROE of 15.4% are respectable but well below the 20%+ threshold I require for sustained quality designation. In a skilled nursing facility (SNF) business, returns are structurally capped by Medicare/Medicaid reimbursement rates, labour intensity, and fixed facility costs. This is a fundamentally labour-intensive, government-reimbursed care business — not an asset-light compounder with pricing power. The operating margin of only 8.5% and net margin of 6.8% are thin, signalling limited moat depth; there is no brand, switching cost, or network effect of the kind I look for in a Fundsmith holding.

The roll-up acquisition model is a serious red flag for me. Management is explicitly acquisitive — 45 facilities acquired in 2025 alone, $240M+ capital deployed in acquisitions. Smith openly distrusts serial acquirers; this growth model is exactly what I avoid, as it makes organic return quality difficult to isolate, creates integration risk, and often flatters earnings with scale that cannot be reproduced without ever-larger M&A. The Hunterbrook short-seller report (June 2026) alleging understaffing and patient neglect adds an unresolved regulatory/reputational overhang that I cannot dismiss — if the clinical quality narrative is undermined by cost-cutting, the CMS star-rating advantage erodes. Class-action probes are now in play.

Valuation is not stretched on a DCF basis (intrinsic $259 vs price $163, 59% upside per the model), and at 19.3x FCF it is not egregiously expensive for a compounder. P/E of 27.7x is moderate for the growth rate (PEG 1.5). However, these valuations assume the 12% FCF growth rate holds — which is contingent on continued acquisition activity AND organic occupancy gains, both of which carry execution risk.

Net: Ensign is a decent business, not a Fundsmith-grade business. Too acquisitive, too thin-margined, too government-dependent, returns below my threshold. Worth monitoring if allegations are resolved and organic returns improve.

Key points

FCF of $493M exceeds net income of $344M — excellent cash conversion, earnings quality confirmed
Net cash balance sheet ($366M net cash, D/E 0.06x) — no leverage concern, unusual for SNF sector
Revenue CAGR 18.5% over 3 years with consistent earnings beats and 22-year dividend growth
FCF margin ~9.8%, capex only $71M vs $564M operating cash flow — genuinely light capex
DCF implies 59% upside ($259 intrinsic vs $163 price), bear case still $200 — margin of safety present
Q1 2026 surpassed estimates; Q3 2025 same-store occupancy at 83% all-time high with organic runway to 85-88%

Red flags

ROIC 14.2% and ROE 15.4% — below Fundsmith's 20%+ threshold; government reimbursement structurally caps returns
Operating margin only 8.5% — thin, indicating limited pricing power and moat; labour-intensive, not asset-light in the moat sense
Serial acquisitive roll-up model: 45 facilities in 2025, $240M+ deployed — exactly the M&A-driven growth Smith distrusts
Hunterbrook short-seller report (June 2026) alleges understaffing and patient neglect; class-action probes filed — unresolved regulatory/reputational risk
Government-dependent revenue (Medicare/Medicaid) subject to reimbursement policy risk outside management's control
Business quality does not meet Fundsmith threshold: no brand, switching costs, or network effects; structurally thin-margin regulated service

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

ENSG presents a genuine forward earnings growth story — Q3 2025 showed +18% YoY adjusted EPS, guidance raised to $6.48–$6.54, and organic occupancy runway (83% → potential 88%) is a real second-derivative positive. Revenue CAGR of 18.5% over 3 years and FCF of $493M with 12% projected growth are not trivial. The demographic tailwind (80+ population +50% by 2035) is a durable secular wave. However, the Druckenmiller lens demands tape confirmation and a clean, readable thesis — and ENSG currently has neither. The stock is sitting at its 52-week LOW (the fact base shows high_52w = 163.05 = same as last close, meaning the current price IS the 52-week low, not the high which was $218). That is a significant tape red flag — the stock has been in persistent distribution, falling from $218 to $163, a ~25% decline. The Hunterbrook short report (June 8, 2026) alleging understaffing and patient neglect has introduced a serious litigation and regulatory overhang with class-action probes filed (Kessler Topaz, Rosen Law). This creates exactly the kind of opacity and undefined downside that makes concentrated, fast-moving bets impossible to manage. The alleged business model risk — that profitability is generated by understaffing — if substantiated even partially, threatens the CMS star-rating moat that underpins the entire bull thesis. Liquidity environment: no explicit Fed easing catalyst identified. Management's silence on the short report is ambiguous. The buyback expansion ($40M → $100M) is a modest confidence signal but does not offset the regulatory/reputational uncertainty. The DCF suggests 59% upside (base $258.77 vs. $163) but Druckenmiller does not buy cheap — he buys right, meaning price action and earnings trajectory must agree. With the tape in freefall and an unresolved short thesis hanging over the story, this is a 'wait for dust to settle' situation, not a concentrated entry.

Key points

Forward earnings inflecting strongly: adjusted EPS +18% YoY in Q3 2025, guidance raised mid-year, Q1 2026 beat estimates — the earnings revision direction is positive
Organic occupancy runway (83% → 88%) is a genuine second-derivative catalyst requiring no incremental capex — pure margin expansion potential equivalent to 8–17 new 100-bed facilities
18.5% 3-year revenue CAGR with FCF of $493M and minimal debt (D/E 0.06x, net cash positive $366M) gives clean balance sheet to judge trajectory
Demographic secular wave is durable and management-confirmed: 80+ population +50% by 2035, declining dependency ratio — the 'wave' is real
$40M→$100M buyback authorization signals management conviction; 22-year dividend growth streak shows capital discipline
DCF intrinsic value $258.77 implies 59% upside with bear case $199.93 — meaningful margin of safety if thesis holds

Red flags

TAPE IS BREAKING DOWN: stock at 52-week low (~$163 vs. $218 high), ~25% decline — Druckenmiller's first rule is do not fight the tape or add to losers; price action directly contradicts the bull thesis
Hunterbrook short report (June 8, 2026) alleges understaffing and patient neglect — if even partially validated, threatens the CMS 4-5 star rating moat that is the core competitive differentiator; this introduces undefined downside that makes position-sizing impossible
Class-action probes (Kessler Topaz, Rosen Law) filed — legal overhang creates opacity in forward earnings, potential settlement costs, and reputational risk with referral sources and managed care partners
No clear invalidation point on the short thesis: management has not publicly rebutted allegations (silence ambiguous), regulatory investigation timeline unknown — thesis cannot be cleanly managed
No identifiable macro/liquidity catalyst: no Fed easing tailwind in evidence; healthcare/SNF sector itself under pressure (sector already 'beaten down' per retail commentary); not riding a liquidity wave
SNF sector crowded with known headwinds: Medicaid reimbursement pressure, state budget risks, labor costs — short report hit sector when 'already beaten down,' per experienced retail observer

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

Ensign Group is a profitable, growing, dividend-paying healthcare operator with a long earnings track record — the kind of established business Graham could evaluate. However, applying my quantitative screens rigorously reveals significant shortcomings that prevent a clear 'pass' verdict. On the positive side: the DCF intrinsic value of $258.77 implies a ~59% upside from $163.05, which if taken at face value represents a meaningful margin of safety. Free cash flow is robust at $493M (FCF yield ~5.2% on market cap), and the P/FCF of 19.3x is more palatable than the P/E of 27.7x. Revenue CAGR of 18.5% over three years and a 22-year uninterrupted dividend streak satisfy my dividend and earnings stability criteria. ROE of 15.4% and ROIC of 14.2% indicate genuine earning power on assets. Net debt is negative (-$366M), meaning the company holds net cash — a balance sheet positive. However, my quantitative tests flag serious concerns: (1) P/E of 27.7x far exceeds my defensive ceiling of 15x; (2) P/B of 4.27x is high; the combined P/E × P/B = 27.7 × 4.27 = 118.3, grossly exceeding my maximum of 22.5 — this single test alone would disqualify it for my defensive portfolio. (3) Current ratio of 1.42 falls well below my standard of 2.0, and current assets ($1.27B) are only 1.42x current liabilities ($894M), not the 2x I require. (4) Long-term debt ($137M) is modest relative to working capital ($378M), so that test passes. (5) The short-seller report from Hunterbrook alleging understaffing and patient neglect introduces regulatory and reputational risk that a conservative investor cannot ignore — these are not merely market noise but potential threats to the franchise value and regulatory standing. (6) The DCF's terminal value represents 81% of enterprise value, making the intrinsic value highly sensitive to growth assumptions that I find speculative rather than demonstrated. The 12% FCF growth assumption applied to a healthcare services company facing reimbursement and staffing risks is not conservative. In sum: this is a quality business but not a Graham-style value opportunity at current prices. I would need to see either a much lower price (perhaps $80-100 range) to achieve true margin of safety against conservatively estimated earnings power, or a balance sheet restructuring that strengthens the current ratio. The short-seller investigation and class-action probes add uncertainty that further warrants caution.

Key points

22-year uninterrupted dividend streak satisfies my key durability criterion; quarterly $0.065/share maintained
Net cash position (-$366M net debt) is a genuine balance-sheet positive; long-term debt of $137M modest
DCF base case at $258.77 implies 59% upside — if assumptions hold, margin of safety exists at current price
FCF of $493M and FCF margin of 9.8% demonstrate real earnings power, not accounting fiction
ROIC of 14.2% and ROE of 15.4% indicate the business earns above its cost of capital consistently
Revenue CAGR of 18.5% over three years shows demonstrated growth, though mostly acquisition-driven
Q1 2026 earnings surpassed estimates; management raised FY2025 guidance — operational momentum intact

Red flags

P/E of 27.7x nearly doubles my 15x defensive ceiling — not a value price by any Graham measure
P/E × P/B product of ~118 far exceeds my 22.5 maximum — fails the combined valuation test decisively
Current ratio of 1.42 falls below my required 2.0 minimum; current assets only 1.42x current liabilities
DCF terminal value constitutes 81% of enterprise value — intrinsic value rests on speculative future growth, not demonstrated assets
Hunterbrook short report alleging patient neglect, understaffing, metric-gaming introduces regulatory and franchise risk
Class-action probes by Kessler Topaz and Rosen Law Firm add legal uncertainty not quantifiable from available data
Price at 52-week high ($163.05) — Mr. Market is optimistic, not pessimistic; I prefer buying from fear not enthusiasm
12% FCF growth assumption in DCF is aggressive for a Medicare/Medicaid-dependent operator facing reimbursement uncertainty

Seth Klarman — 🟡 watch · 52/100 · medium confidence

ENSG presents a genuinely interesting tension for a value lens: the DCF suggests ~59% upside to a $258 intrinsic value, the balance sheet is conservatively managed (net cash position of ~$366M, D/E of 0.06, current ratio 1.42), and the business generates real, consistent free cash flow ($492M FCF, 9.8% FCF margin). However, several Klarman-critical concerns prevent a full pass. First, the margin of safety, while real on a base-case DCF, is not durable against a conservative stress test. The DCF is 81% terminal value — meaning the price today is essentially a bet on perpetual compounding at 12% FCF growth, which is an assumption-heavy, not asset-backed, valuation floor. A Klarman-style liquidation or conservative going-concern value would look very different: tangible book is substantially impaired by leasehold/goodwill complexity in a healthcare services rollup, and the REIT subsidiary (Standard Bear) adds valuation opacity. Second, the Hunterbrook short-seller report alleging understaffing, patient neglect, and metric-gaming introduces a genuine regulatory/legal tail risk that could impair the going-concern value. Two law firms have filed class-action probes. If substantiated, CMS reimbursement pressure, state licensing risk, or staffing mandates could structurally compress margins — exactly the scenario where a 'cheap' stock becomes permanently impaired. Third, the business model's profitability arguably rests on labor arbitrage (lean staffing in Medicare/Medicaid SNFs), which is politically and regulatorily vulnerable, particularly in the current policy environment. Fourth, while $163 is 25% below the 52-week high ($218) and below the DCF bear case ($199), it is not at a 'fat pitch' discount to a conservative, asset-backed floor — it is at a fair-to-modest discount to an optimistic earnings-multiple valuation (P/FCF 19x, P/E 27.7x). These are growth multiples, not distressed value multiples. The buyback ($40M→$100M) is a mild positive signal, but at 9.5B market cap it is cosmetic. RBC reiterating is noise. The organic occupancy story (83% to 85-88%) is real but long-dated and operationally contingent. Net: this is a quality business at a modest discount to a growth-dependent value, not a distressed asset at a large discount to a conservative floor. Worth monitoring — especially if the short-seller allegations resolve favorably and the stock corrects further — but does not clear Klarman's margin-of-safety bar today.

Key points

DCF intrinsic value of $258.77 implies 59% upside, but 81% of that value resides in the terminal value — not asset-backed, highly assumption-sensitive
Balance sheet is genuinely clean: net cash ~$366M, long-term debt only $137M, D/E 0.06, $1B+ liquidity — this is a real Klarman positive that limits downside
FCF generation is robust and consistent: $492M in 2025, 9.8% FCF margin, operating cash flow $564M — real cash, not accounting construct
P/FCF of 19x and P/E of 27.7x are growth-company multiples, not value multiples; there is no classic margin of safety at current price versus normalized earnings power
Hunterbrook/class-action risk introduces genuine tail: if CMS scrutiny or staffing mandates follow, operating margins (currently 8.45%) could compress materially
Revenue CAGR of 18.5% (3-year) is impressive but reflects acquisitions; organic normalized earnings power is harder to pin down for a conservative going-concern appraisal
Standard Bear REIT subsidiary adds complexity and opacity to consolidated accounting — a Klarman concern about illusory asset value
Stock is 25% below 52-week high ($218→$163), suggesting some technical/forced selling from short report — but not yet at a distressed-price discount

Red flags

Hunterbrook short report + dual class-action filings (Kessler Topaz, Rosen Law) create unquantified legal/regulatory tail risk that could impair the going-concern floor
DCF is 81% terminal value — intrinsic value depends entirely on sustained 12% FCF growth and 2.5% terminal growth; stress-testing to 8% growth and 7% WACC+ collapses fair value toward or below current price
Operating model alleged to rely on labor under-investment in Medicare/Medicaid SNFs — politically and regulatorily vulnerable in current environment
No catalyst beyond organic growth to close the gap; this is a 'hold and compound' bet, not a special situation with a hard value unlock
P/E 27.7x and P/FCF 19x are not distressed or value multiples; paying a growth premium for a business facing serious allegations is not Klarman-style risk/reward
Goodwill and intangibles from serial acquisitions likely inflate book value ($4.27x P/B); liquidation value of SNF operator assets well below stated book
Management silent on Hunterbrook allegations in available material — no rebuttal, no operational commentary post-June 2026 report

Forensic Short-Seller (Chanos/Einhorn-style) — 🟡 watch · 48/100 · medium confidence

ENSG passes the fundamental earnings-vs-cash test reasonably well — operating cash flow ($564M) exceeds net income ($344M), and free cash flow ($493M) is robust positive, which is the opposite of the classic Chanos red flag. However, several forensic concerns warrant a 'watch' rather than a clean pass: (1) A serious short-seller report (Hunterbrook, June 2026) alleging understaffing, patient neglect, and metric-gaming has emerged alongside class-action probes from Kessler Topaz and Rosen Law Firm — these are litigation and regulatory tail risks that are structurally unquantifiable from public filings alone; (2) ENSG is a serial acquirer (45 deals in 2025 alone, $240M+ deployed YTD) — this model generates goodwill, intangible assets, and lease liabilities that can mask true economic performance and creates ongoing integration risk; (3) The capex figure reported ($71.5M) appears to be from 2019 rather than 2025, which is a significant data anomaly — if current capex is materially higher (likely given the acquisition pace), the true FCF figure could be overstated; (4) The Standard Bear REIT subsidiary adds consolidation complexity and opacity — sale-leaseback structures between related entities can be used to accelerate revenue recognition or obscure leverage; (5) Long-term debt appears extremely low ($137M) relative to total liabilities ($3.23B), implying the bulk of liabilities are operating lease obligations — GAAP lease accounting (ASC 842) means the true financing burden may be understated in traditional debt metrics; (6) Management silence on the Hunterbrook allegations is a yellow flag — Chanos-style analysis rewards managements that engage directly with specific accounting criticisms; (7) The 3-year revenue CAGR of 18.5% driven substantially by acquisitions — not organic growth — means quality-of-earnings depends heavily on purchase accounting, and amortization of acquired intangibles may be distorting margins; (8) Insider selling and Form 4 data not available in the fact base — a material gap. The kill question: this becomes a clear short if (a) the Hunterbrook/class-action allegations are substantiated by regulatory action or restatement, (b) the operating lease liability structure is revealed to be structurally leveraged beyond disclosed metrics, or (c) FCF conversion deteriorates as acquisition-era liabilities mature. What disproves the bear case: management engaging transparently with allegations, clean regulatory audits, and FCF continuing to exceed net income through the next 4-6 quarters without goodwill impairment charges.

Key points

OCF ($564M) > Net income ($344M) — the primary Chanos test does NOT flag earnings quality concerns at the top level
FCF of $493M is positive and material, representing a 9.8% margin — not a cash-burning growth story
However, capex data appears dated (labeled 2019) — if true 2025 capex is higher, FCF is overstated and the quality-of-earnings picture changes materially
Serial acquirer model (45 deals in 2025) creates ongoing goodwill and intangible asset accumulation — purchase accounting can temporarily inflate margins on acquired assets
Total liabilities of $3.23B vs. long-term debt of only $137M implies the balance sheet is dominated by operating lease obligations — true leverage understated by D/E ratio of 0.06
Standard Bear REIT subsidiary (sale-leaseback with affiliated and third-party tenants) adds consolidation opacity — a classic structure for obscuring economic leverage
Revenue CAGR of 18.5% is largely acquisition-driven, not organic — quality of earnings depends on integration success and purchase price discipline
Hunterbrook short report + two class-action law firm investigations filed as of June 2026 — litigation and regulatory risk not yet quantifiable
Management has not publicly rebutted specific allegations (per available material) — promotional silence is a mild negative forensic signal
No insider Form 4 data available — critical gap for Chanos-style analysis

Red flags

Capex field shows 2019 date — data integrity issue that potentially overstates reported FCF if actual 2025 capex is higher
$3.09B gap between total liabilities ($3.23B) and long-term debt ($137M) is largely unexplained in summary data — likely operating leases but warrants deep footnote review
Hunterbrook report (June 8, 2026) alleges understaffing and metric-gaming — if CMS quality metrics are gamed, the clinical differentiation thesis collapses and reimbursement risk rises
Two securities class-action investigation firms (Kessler Topaz, Rosen) announced probes within weeks of short report — elevated litigation risk
45 acquisitions in a single year creates massive integration complexity and goodwill buildup — impairment risk is structurally elevated
Standard Bear REIT related-party dynamics not fully disclosed in summary — sale-leaseback accounting between Ensign-operated facilities and affiliated REIT can frontload gains
No insider selling or buying data available — inability to assess management conviction or distribution patterns is a forensic gap
Management's decentralized 'AIT pipeline' model is operationally attractive but creates audit complexity across hundreds of subsidiaries — a structural audit risk

Walter Schloss — 🔴 avoid · 28/100 · high confidence

ENSG fails nearly every Schloss deep-value criterion. The stock trades at 4.27x book value — far above the tangible-asset anchor Schloss demanded. At $163.05, it sits at its 52-week high (0% below), not the beaten-down, out-of-favor territory Schloss hunted. The business is a skilled nursing/senior living operator whose value resides overwhelmingly in going-concern earnings power, reimbursement relationships, CMS star ratings, and operational know-how — intangibles that cannot be appraised off the balance sheet. Tangible book is further diminished by goodwill/intangibles from an aggressive acquisition program (73+ ops since 2024). While the balance sheet is conservatively leveraged (D/E 0.06, long-term debt only $137M vs. $2.2B equity), that virtue is completely overwhelmed by the rich price-to-book multiple. The DCF intrinsic value of $258.77 is compelling to a growth or GARP investor, but Schloss didn't buy future earnings streams — he bought assets at a discount. P/FCF of 19.3x and P/E of 27.7x are not cheap on any absolute basis he would recognize. The Hunterbrook short-seller report alleging understaffing and metric-gaming adds reputational and regulatory risk that could impair the earnings-dependent value proposition. The $40M-$100M buyback at 52-week highs is a capital-allocation negative from a Schloss perspective — he preferred companies buying back stock when it was cheap, not at peaks. Quarterly dividend of $0.065/share (yield ~0.16%) is nominal and provides no meaningful income cushion. The business is operationally interesting and financially sound, but it is a growth-quality compounder priced as such — the antithesis of a Schloss statistical bargain.

Key points

Price-to-book of 4.27x; Schloss sought near or below tangible book — this is ~4x too expensive on his primary metric
Stock at 52-week HIGH ($163.05 = 52w high per price data), not the beaten-down territory Schloss required
Balance sheet leverage is genuinely conservative (D/E 0.06, $137M LTD vs. $503M cash) — the one criterion it meets
Value depends entirely on earnings power, reimbursement rates, and CMS quality ratings — no hard-asset floor independent of operations
Aggressive acquisition-driven growth model adds goodwill/intangibles to book, further depressing tangible asset support
Dividend yield ~0.16% annually — negligible; does not compensate long-term patient holder waiting for value recognition
P/E 27.7x and P/FCF 19.3x — not statistically cheap on any absolute measure Schloss used

Red flags

Trading at 52-week high — Schloss explicitly avoided stocks near highs; he bought what was out of favor
P/B 4.27x far exceeds Schloss's threshold; asset-light intangible-heavy SNF model has no tangible book cushion
Hunterbrook short-seller allegations (understaffing, metric gaming, patient neglect) plus class-action probes introduce regulatory/legal tail risk that could impair earnings-dependent value
Buyback authorized at all-time highs ($40M-$100M) — from a Schloss view this destroys per-share asset value rather than creating it
Business complexity: REIT subsidiary (Standard Bear), 149 properties, multi-state regulatory environments — too opaque for Schloss's simple-filing test
No insider buying signals visible in the fact base; no mention of meaningful management ownership stake that would align interests in a Schloss-style way
Earnings-forecast-dependent DCF ($258 intrinsic) is precisely the type of thesis Schloss rejected — he wanted assets you could see and touch, not discounted cash flow projections

Fact base appendix

Price

last_close: 163.05
as_of: 2026-06-26
high_52w: 163.05
low_52w: 163.05
pct_below_52w_high: 0.0

Fundamentals

last_price: 163.05
market_cap: 9529522470
fifty_two_week_low: 134.79
fifty_two_week_high: 218.0
beta: 0.682
change_pct: -1.62302
currency: USD
sector: Healthcare
industry: Medical - Care Facilities
price_source: fmp_profile
bars: 1
entity: ENSIGN GROUP, INC
fiscal_year: 2025
revenue: 5032118000
revenue_period: 2025-12-31
net_income: 343971000
net_income_period: 2025-12-31
operating_income: 425306000
operating_income_period: 2025-12-31
operating_cash_flow: 564270000
operating_cash_flow_period: 2025-12-31
capex: 71541000
capex_period: 2019-12-31
total_assets: 5462970000
total_assets_period: 2025-12-31
total_liabilities: 3228146000
total_liabilities_period: 2025-12-31
current_assets: 1272304000
current_assets_period: 2025-12-31
current_liabilities: 894346000
current_liabilities_period: 2025-12-31
stockholders_equity: 2231725000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 503881000
cash_and_equivalents_period: 2025-12-31
long_term_debt: 137529000
long_term_debt_period: 2025-12-31
shares_outstanding: 58112780
operating_margin: 0.0845
net_margin: 0.0684
roe: 0.1541
debt_to_equity: 0.0616
current_ratio: 1.4226
roic: 0.1418
free_cash_flow: 492729000
fcf_margin: 0.0979
pe_ratio: 27.7
price_to_fcf: 19.34
price_to_sales: 1.89
revenue_cagr: 0.1848
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
price_to_book: 4.27
earnings_yield: 0.0464
peg: 1.5

Filings reviewed

8-K (2026-06-15) https://www.sec.gov/Archives/edgar/data/1125376/000112537626000031/ensg-20260612.htm
8-K (2026-06-10) https://www.sec.gov/Archives/edgar/data/1125376/000112537626000029/ensg-20260513.htm
10-Q (2026-04-30) https://www.sec.gov/Archives/edgar/data/1125376/000112537626000021/ensg-20260331.htm
10-K (2026-02-04) https://www.sec.gov/Archives/edgar/data/1125376/000112537626000007/ensg-20251231.htm
10-Q (2025-11-03) https://www.sec.gov/Archives/edgar/data/1125376/000112537625000170/ensg-20250930.htm
10-K (2025-02-05) https://www.sec.gov/Archives/edgar/data/1125376/000112537625000021/ensg-20241231.htm

Other sources

[news] $ENSG Stock News: Ensign Stock Dropped 8% after Neglect - GlobeNewswire
[news] Here's Why Investors Continue to Hold Ensign Group Stock - Yahoo Finance
[news] Ensign Group authorizes $40 million stock repurchase program - TradingView
[news] Ensign Group (ENSG) Board approves new $40M stock repurchase program - Stock Titan
[news] RBC Capital reiterates Ensign Group stock rating after short report - Investing.com
[news] Ensign Group (ENSG) Q1 Earnings Surpass Estimates - Yahoo Finance
[news] Ensign Group, Inc. Actuals & Estimates (BOATS:ENSG) - TradingView
[news] ENSG Investigation: Kessler Topaz Meltzer & Check, LLP Encourages The Ensign Group, Inc. (NASDAQ: ENSG) Investors to Contact the Firm - PR Newswire
[news] The Ensign Group, Inc. Announces Increased Stock Repurchase Authorization - 富途牛牛
[news] The Ensign Group, Inc. (ENSG) Stock Analysis: A Healthy 47.55% Upside Potential In Healthcare - DirectorsTalk Interviews
[news] Ensign Group slides as short-seller report sparks investor concern - Quiver Quantitative
[news] Rosen Law Firm Encourages The Ensign Group, Inc. Investors to Inquire About Securities Class Action Investigation – ENSG - Business Wire
[news] Ensign Group, Inc. Actuals & Estimates (NASDAQ:ENSG) - TradingView
[news] EGB Forecast — Price Target — Prediction for 2027 - TradingView
[news] Price to earnings forward of The Ensign Group, Inc. – NASDAQ:ENSG - TradingView
[news] Ensign Group, Inc. Actuals & Estimates (SWB:EGB) - TradingView
[news] The Ensign Group Declares Quarterly Cash Dividend of $0.0650 Per Share - Quiver Quantitative
[news] Ensign Group sticks with a 6.5-cent quarterly cash dividend - Stock Titan
[discussion] [Bullish] $ENSG
[discussion] Wall St is expecting 1.85 EPS for $ENSG Q2 [Reporting 07/23 AMC] http://www.estimize.com/intro/ensg?
[discussion] $ENSG (+0.0% pre) (This is the typical "no response" response to a big short report) Ensig
[discussion] $ENSG need to wait until the dust settles on this one..
[discussion] $ENSG Muddy is the shizzle.

https://x.com/muddywatersre/status/2065127144468971858?s=20

[discussion] [Bearish] $ENSG Rekt.
[discussion] $ENSG guessing an institution just dumped their sizable position?
[discussion] Check out this weekly & daily alignment on $PACS. Setting up perfectly — same way their business
[discussion] $ENSG Current Stock Price: $158.03 Contracts to trade: $160.0 ENSG Jun 18 2026 Call Entry: $2.00 Exi
[discussion] $ENSG Hunterbrook shorts typically rebound for one reason or another. This reports hits a SNF when t
[discussion] $ENSG the bear thesis is the company understaffs their facilities and the understaffing creates 100%
[discussion] RECAP 6/8 +Pos Comments: $ZVRA + Cantor $WIX + Benchmark

RECAP 6/8 -Neg Comments: $NRIX - WFC

[discussion] Hunterbrook report accuses $ENSG of understaffing, gaming metrics, and patient neglect. https://notr
[discussion] $ENSG oh, short seller report. RIP.
[discussion] $PACS major indices green. VIX down. $PACS and $ENSG RED.

Classic. I really don’t get it.

[earnings_call] The Ensign Group, Inc ENSG Q3 2025 Earnings Call

Generated 2026-07-17T19:51:16 · est. cost $1.51

What each investor thinks

Valuation Referee (Damodaran-style) Referee

pass · 74

Joel Greenblatt Value

pass · 74

Charlie Munger Quality

pass · 74

Michael Mauboussin Quality

pass · 74

Ray Dalio Risk

pass · 72

AI & Disruption Referee (Christensen-style) Referee

pass · 72

Chuck Akre Quality

watch · 62

Warren Buffett Quality

watch · 62

Bruce Greenwald Value

watch · 62

Philip Fisher Growth

watch · 58

Peter Lynch Growth

watch · 58

Howard Marks Risk

watch · 55

Terry Smith (Fundsmith) Quality

watch · 55

Stanley Druckenmiller Risk

watch · 52

Benjamin Graham Value

watch · 52

Seth Klarman Value

watch · 52

Forensic Short-Seller (Chanos/Einhorn-style) Referee

watch · 48

Walter Schloss Value

avoid · 28

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →

Ensign Group, Inc

ENSIGN GROUP, INC (ENSG) — Council Assessment

🟡 WATCH · Score 58/100 · medium confidence

360 narrative — news & sentiment digest

ENSG — ENSIGN GROUP, INC.

Management commentary (earnings call)

Recent developments

Bull narrative

Bear narrative

Retail sentiment

Caveats

Bull case

Bear case

Dissent — where the council disagrees

Key risks

Catalysts

DCF valuation (finance-expert model)

Short-sell evaluation

Council scorecard

Member reasoning

Valuation Referee (Damodaran-style) — 🟢 pass · 74/100 · medium confidence

Joel Greenblatt — 🟢 pass · 74/100 · medium confidence

Charlie Munger — 🟢 pass · 74/100 · medium confidence

Michael Mauboussin — 🟢 pass · 74/100 · medium confidence

Ray Dalio — 🟢 pass · 72/100 · medium confidence

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

Chuck Akre — 🟡 watch · 62/100 · medium confidence

Warren Buffett — 🟡 watch · 62/100 · medium confidence

Bruce Greenwald — 🟡 watch · 62/100 · medium confidence

Philip Fisher — 🟡 watch · 58/100 · medium confidence

Peter Lynch — 🟡 watch · 58/100 · medium confidence

Howard Marks — 🟡 watch · 55/100 · medium confidence

Terry Smith (Fundsmith) — 🟡 watch · 55/100 · medium confidence

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

Seth Klarman — 🟡 watch · 52/100 · medium confidence

Forensic Short-Seller (Chanos/Einhorn-style) — 🟡 watch · 48/100 · medium confidence

Walter Schloss — 🔴 avoid · 28/100 · high confidence

Fact base appendix

Valuation Referee (Damodaran-style) Referee

Joel Greenblatt Value

Charlie Munger Quality

Michael Mauboussin Quality

Ray Dalio Risk

AI & Disruption Referee (Christensen-style) Referee

Chuck Akre Quality

Warren Buffett Quality

Bruce Greenwald Value

Philip Fisher Growth

Peter Lynch Growth

Howard Marks Risk

Terry Smith (Fundsmith) Quality

Stanley Druckenmiller Risk

Benjamin Graham Value

Seth Klarman Value

Forensic Short-Seller (Chanos/Einhorn-style) Referee

Walter Schloss Value